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Abstract/Summary
N6-methyladenosine (m6A) is one of the most prevalent RNA modiﬁcations present within messenger
RNAs (mRNAs), with an average of 3-5 modiﬁed adenosines per transcript. The methyltransferase-like
protein 3 (METTL3) and methyltransferase-like protein 14 (METTL14) have been reported to form a sta-
ble dimeric complex that is responsible for the formation of m6A within mRNAs. The METTL14 subunit
of this methyltransferase complex has been proposed to be the catalytic subunit. This conclusion was,
however, drawn from analyzing each subunit separately and not within the context of the assembled
complex. Here, point mutations within METTL3 resulted in the complete loss of catalytic activity within
the binary complex, whereas no such eﬀect was observed when mutating METTL14. In addition to
this, cross-linking experiments using tritiated S-adenosyl-methionine (SAM) and recombinantly puriﬁed
METTL3/14 suggest that METTL3 is also the only subunit that can eﬃciently bind to the methyl donor. A
third aspect that was analyzed in this work was if the METTL3/14 complex can speciﬁcally recognize its
RNA substrate. Electrophoretic mobility shift assays (EMSAs) that were conducted suggest that the pro-
tein complex mostly binds to polyanionic molecules in an unspeciﬁc manner and that target speciﬁcity
is introduced by other means.
During the experimental phase of this work, not much was known about the architecture of themethyl-
transferase. Here,experiments using truncation constructs of METTL14 provide evidence that the MT-
A70 domain of this protein is essential for the dimerization withMETTL3. An additional protein, namely
the Wilms’ tumor 1-associating protein (WTAP), has been reported to stably associate with the methyl-
transferase complex through a direct interaction with METTL3. This interaction between METTL3 and
WTAPwas also examined in this work. The data collected from immunoprecipitation experiments could
demonstrate that the ﬁrst N-terminal α-helix within METTL3 binds to a small protein region within
WTAP’s N-terminus. Closer examination of these identiﬁed interaction surfaces led to the hypothesis
that most likely coiled-coils promote the observed METTL3-WTAP interaction.
All of the above investigated proteins are localized within the cell nucleus. Many nuclear proteins rely
on a nuclear localization signal (NLS) for them to be translocated across the nuclear envelope. Here,
mutational analysis revealed thatWTAP andMETTL3 each possess a classical NLS sequence that is func-
tional. For METTL14, this work provides evidence that METTL14 does not have a NLS embedded within
its primary sequence and that its localization depends on the heterodimerization with METTL3.
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1. Introduction
1.1 The epitranscriptome
The genetic information encoded in DNA and RNA is build-up by the four diﬀerent bases adenine,
guanine, cytosine and thymine, or in case of RNA, uracil. Early analysis of the total pool of RNA syn-
thesized by the cell, termed the transcriptome, has revealed that other bases besides the canoni-
cal ones can be found in large quantities. To date, over 140 diﬀerent base modiﬁcations have been
identiﬁed in RNA and arise through modiﬁcation reactions of the "standard" bases that occur post-
transcriptionally.1 Some examples for non-canonical nucleosides present in RNAs are pseudouridine
(Ψ), inosine, 5-carbamoylmethyluridine and N6-methyladenosine (m6A). Additionally to the presence
of a variety of bases, it has been reported that both the ribose and the phosphate moiety within RNA
can undergo diﬀerent modiﬁcations as well.2–6 This collection of diﬀerent RNA modiﬁcations adds a
second layer of information onto the transcribed genetic information and has coined the term of the
epitranscriptome.7–9
It has been proposed that several of these modiﬁcations found in diﬀerent RNA species inﬂuence the
stability or structure of the RNA. For instance, 5-methylcytosine (m5C) can be found in several diﬀerent
transfer RNAs (tRNA). Publications have shown that the presence of this modiﬁcation at the C38 posi-
tion of the tRNAs AspGTC, ValAAC and GlyGCC, catalyzed by the protein Dnmt2 (also known as Trdmt1),
enhances the stability of the RNA under normal and stress conditions.10–13 An example for the struc-
tural inﬂuence of an RNAmodiﬁcation is the pseudouridylation of tRNAs. It has been reported that this
modiﬁcation can rigidify the tRNA structure by locking the ribose ofΨ in the C3’-endo conformation.14, 15
The importance of RNA modiﬁcations is, however, not only conﬁned to the structure and stability of
certain transcripts. It has been reported that non-canonical bases are vital for the function of diﬀerent
ribonucleoprotein complexes. Ψ is again a prominent example. This base modiﬁcation inﬂuences the
binding aﬃnity of the ribosome towards tRNAs. Therefore, a depletion of pseudouridylation leads to a
reduction of translation eﬃciency and ﬁdelity.16–18 Another base modiﬁcation that has an inﬂuence on
translation is 7-methylguanine (m7G) that forms the "methyl-cap" of mRNAs.19–21 This modiﬁcation is
established at the 5’ end of mRNAs and is directly and speciﬁcally bound by a protein termed eukaryotic
initiation factor 4E (eIF4E).22–24 eIF4E together with eIF4A and eIF4G forms a complex (termed eIF4F)
that is essential for the recruitment of the 43S pre-initiation complex to the mRNA.25–28 m7G-binding
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facilitated by eIF4E is considered the rate-limiting and vital step in the initiation of protein synthesis.29
Besides translation, them7G-cap is also responsible for the nuclear export ofmRNAs and is considered a
general stability factor for these transcripts.30–33 Taken together, these examples highlight the necessity
and importance of RNA modiﬁcations and their contribution to a variety of cellular processes.
Even though the large repertoire of diﬀerentmodiﬁcations have been knownnow for over half a century,
the exact molecular modes of action for many of them remain elusive. A great majority of these non-
canonical RNA building blocks have been identiﬁed and studied in tRNAs and ribosomal RNAs (rRNA).
Analysis of RNA modiﬁcations was mostly restricted to these two ncRNA species, as these transcripts
are highly abundant in the cell and larger quantities can be easily extracted. It was not until recently
that more sensitive methods have been developed, allowing the detection and deeper analysis of RNA
modiﬁcations in all classes of transcripts present in a cell.
1.2 Eukaryotic internal mRNA modiﬁcations
It was long thought that eukaryotic mRNAs harbored only a handful of modiﬁcations and that their
presence was restricted to the 5’- and 3’-end of the transcript. The m7G-cap and 2’-OH methylation
of the ﬁrst two transcribed nucleotides are the most commonly known representatives of mRNA mod-
iﬁcations.34–39 However, recent publications could show that some of the same modiﬁcations found
in ncRNAs were also present in mRNAs of diﬀerent eukaryotes.40,41 So far the nucleosides inosine, Ψ,
m5C, N1-methyladenosine and m6A have been identiﬁed in internal sequences of mRNAs (Fig. 1.1).
2
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Figure 1.1 Chemical structure of basemodiﬁcations found in the internal sequences of eukaryotic mRNAs The nucleosides in-
osine, N6-methyladenosine, pseudouridine, 5-methylcytidine and N1-methyladenosine have been found in internal sequences
of eukaryotic mRNAs. All modiﬁcations are established by highly specialized enzymes that act upon the mRNA posttranscrip-
tionally.
1.2.1 Inosine
Insosine is an RNAmodiﬁcation that has been extensively studied in mRNA during the last two decades.
The base adenine is converted into hypoxanthine during a process that has been termed A-to-I RNA
editing. This process has been ﬁrst described to be involved in the unwinding of exogenous double-
stranded RNA (dsRNA) in crude extracts derived from Xenopus laevis oocytes, embryos or even from
mammalian cells.42–44 This activity was distinct from that observed in the modiﬁcation of tRNAs and
of the purine catabolism. Later, proteins belonging to the adenosine deaminase acting on RNA (ADAR)
family were identiﬁed as the enzymes responsible for the speciﬁc activity observed in Xenopus.45,46
The presence of ADAR-mediated formation of inosine in mRNA remained a matter of controversy until
several reports have shown that this RNA modiﬁcation was indeed harbored in mRNAs and showed a
tissue-speciﬁc abundance.47–49 Inosine was later readily mapped within mRNAs via high-throughput
sequencing technology and the fact that this non-canonical base is recognized as a guanosine during
reverse transcription (RT).50 Usage of this method led to the identiﬁcation of 1600 genes.48 A to I
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editing seems to be a stochastic event, as no speciﬁc enrichment of this modiﬁcation can be found
within deﬁned regions of mRNA, such as the 5’- or 3’-untranslated region (UTR).
ADAR1 and ADAR2 are the best studied representatives of the ADAR protein family. Investigation of both
enzymes have shed light on howmRNA editing is achieved and what are the biological consequences of
this event. Both ADAR1 and 2 have been shown to localize in the nucleus and modify messenger tran-
scripts.51–53 In addition to its presence in the nucleus, ADAR1 can also be found in the cytoplasm.54, 55
Due to this distribution pattern, the event of A-to-I editing can occur in both cellular compartments.56
A prerequisite for the deamination reaction promoted by ADARs is the presence of a double-stranded
region within the mRNA. These double-stranded regions normally span a length of more than 20 base
pairs (bp) and can be formed inter- or intramolecularly.57 This is the minimal requirement towards
the target for an eﬃcient removal of the amino group at the C6 position of adenine. However, some
sort of speciﬁcity is needed to explain substrates that are either edited exclusively by ADAR1 or ADAR2,
whereas others are modiﬁed by both enzymes.58–60 The necessity of double-stranded regions make
certain transcripts to ideal substrates such as mRNAs that harbor repetitive elements (such as Alu ele-
ments) in their UTRs.61,62 These sequences derived from transposable elements tend to form secondary
structureswith double-stranded regions and can, therefore, be targeted by ADARs. Other sites have also
been identiﬁed within the coding region of mRNAs. Editing events in this region can lead to amino acid
recoding, as inosine is recognized as a guanine by the translation machinery.63–65
Through the event of recoding, some ADAR-targeted transcripts give rise to proteins with a single amino
acid substitution. These in return can have a great impact on the function of the protein.66,67 The pres-
ence of inosine within 3’-UTR suggests that these deamination sites might have a regulatory potential.
Indeed reports have shown that this type of RNA editing can inﬂuence the cellular localization of an
mRNA or even its stability.68–70 Beside the regulation of a single transcript, a single A-to-I editing event
can inﬂuence multiple transcripts. This can be explained through the modiﬁcation of mRNA transcripts
that give rise to a microRNA (miRNA). A deamination of an adenosine within the seed sequence leads
to the regulation of diﬀerent target transcripts compared to the unmodiﬁed miRNA.71 As these molec-
ular consequences suggest, A-to-I RNA editing can have a signiﬁcant biological impact. Studies have
shown that the inactivation of ADARs can lead to severe phenotypes such as embryonic lethality or
death shortly after birth.58, 72, 73 Human diseases have been as well associated with the mutations of
ADAR proteins which lead to neural dysfunction or alteration of skin pigmentation.74, 75
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1.2.2 5-methylcytidine
Methylation at the C5-position of cytosine is a prominent and well studied modiﬁcation in the ﬁeld
of epigenetics.76 The molecular consequence of this DNA modiﬁcation is mostly repression of gene
expression and is essential in several processes such as genomic imprinting, stem cell diﬀerentiation
and transposon silencing.77–80 Thismodiﬁcation is, however, not restricted to DNA.m5C has been found
and studied in diﬀerent ncRNAs such as tRNAs and rRNAs. In 2012, this modiﬁcation has been detected
with the help of bisulﬁte sequencing in diﬀerent human mRNA transcripts as well.81 8495 methylated
cytosinesweremapped and found to be enrichedwithin the 3’-UTR ofmessengers. Controversial to this
ﬁnding, another transcriptome-wide sequencingmethod could not validate these initial ﬁndings.82 This
study involved the treatment of cells with 5-azacytidine coupled with immuno precipitation of the RNA
that incorporated the cytidine analog with an anti-azacytidine antibody. The authors did not selectively
enrich for mRNAs in their experimental design. Therefore, the absence of these transcripts in their
sequencing data could be the result of a reduced sensitivity compared to themRNA enrichment strategy
and the bisulﬁte sequencing approach used by Squires et al.81 Since these initial publications, there have
been no further transcriptome-wide m5C-sequencing reports published. Therefore, the exact number
of transcripts and abundance of this mRNA modiﬁcation has to be further validated.
The methyltransferase(s) responsible for establishing the cytosine methylation is also a matter of de-
bate. Evidence has been provided that the tRNA methytransferases NSun2 and DNMT2 methylate the
5’- and 3’-UTR of diﬀerent mRNAs.81,83 A diﬀerent study concentrating on NSun2 reported that this
protein does not bind mRNAs except for one, namely NSun2.84 Due to the fact that the methyltrans-
ferase(s) has not been clearly identiﬁed, little is known about the exact biological function of m5C in
mRNAs. The purposed enrichment of this modiﬁcation in 3’-UTRs, based on Squires et al., would sug-
gest a regulatory role.81 So far, only a single study hints to a stabilizing eﬀect on the p16INK4 mRNA.83
A diﬀerent study using cells that carry a loss of function mutation in one or both known RNA m5C-
methyltransferases (NSun2 and DNMT2) showed no diﬀerence in mRNA expression or stability when
compared to their wild-type counterparts.13 This suggests that m5C does not have a global stabilizing
eﬀect onmRNA transcripts. Further investigations are needed in order to identify the exactmethytrans-
ferase(s) that establishes cytosine methylation. Furthermore, eﬀorts have to be made in resolving the
conﬂicting claims that are present in the ﬁeld concerning the abundance, presence and function of m5C
within mRNA.
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1.2.3 Pseudouridine
Pseudouridine is one of the more recent RNAmodiﬁcations found within the internal sequences of mR-
NAs. Three independent studies mapped this modiﬁcation within mRNAs using a sophisticated high-
throughput sequencing protocol.85–87 All three groups enriched mRNAs and treated the RNA with N-
cyclohexyl-N’-(2-morpholinoethyl)carbodiimide metho-p-toluene sulfonate (CMC) to selectively label
pseudouridines. The bulky carbodiimide moiety leads to a termination of the reverse transcription re-
action one nucleotide after the pseudouridylated site.88 This approach allowed to map pseudouridines
in 41 to 238 protein coding transcripts in yeast and between 89 to 300 mRNAs in humans, depending
on the study and the bioinformatic pipeline used to analyze the sequencing data.
These transcriptome-wide mapping studies could also elegantly identify the enzymes responsible for
establishing Ψ within messengers. Interestingly, mRNAs share the same modifying proteins as tRNAs
and rRNAs, namely the pseudouridine synthase (PUS) enzymes.85–87 Isomerization of the uridine moi-
ety can be catalyzed by PUS proteins using two diﬀerent strategies. One arm of this protein family binds
snoRNAs of the H/ACA box family that functions as a guide.89,90 The protein Cbf5p in Saccharomyces
cerevisiae and NAP57 in humans is the catalytic subunit of this PUS RNP complex.91–93 The other arm of
the PUS family can generateΨ in a snoRNA independent manner.94–97 In the transcriptome-wide stud-
ies, depletion of either Cbf5porNap57 abolish certain pseudouridine siteswithinmRNAs, whereas other
sites were unaﬀected. The latter suggests that the other sites aremodiﬁed via the snoRNA-independent
mechanism. Deletion strains of S. cerevisiae identiﬁed the proteins Pus1-4p, Pus6p, Pus7p and Pus9 as
the responsible enzymes for the pseudouridylation in mRNA without the necessity of a nucleic acid as
a guide.85,87 In humans, so far only the proteins Pus4 and Pus7 have been linked to the isomerization
of uridine in messengers.87
Mapping ofΨ could show that the modiﬁcation is not enriched within a certain region of a mRNA tran-
script but seem to be evenly distributed.85 To date, little is known about the biological implications of
this mRNA modiﬁcation. Due to the capacity of Ψ to facilitate unusual base pairing, the presence of
this modiﬁcation within an open reading frame (ORF) could lead to a recoding event similar to those
observed for inosine (see 1.2.1). An in vitro study using artiﬁcial mRNA containing Ψ could show that
this non-canonical base can lead to the recoding of a stop-codon into an amino acid and, thus, leads to
the synthesis of a longer polypeptide.98 Interestingly, mRNA pseudouridylation seems to be a regulated
process. Schwartz and colleagues could show that upon heat-shock of S. cerevisiae cultures, Pus7p is
translocated from the nucleus into the cytoplasm. After relocation, Pus7p eﬀectively pseudouridylates
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mRNAs leading to a heat shock speciﬁc proﬁle.87 The induction of pseudouridylation has also been
shown in human cell lines upon serum starvation, underlining that this modiﬁcation can be induced via
external stimuli and this can be mediated into a biological response.85 Further studies will be needed
to investigate other conditions that induce pseudouridylation, its biological impact and how this modi-
ﬁcation is translated into a response.
1.2.4 N1-methyladenosine
N1-methyladenosine (m1A) is the youngest member of internal mRNA modiﬁcations. All what is known
todate about thismRNAbasemodiﬁcation has beendescribedby two independent groups in 2016.99, 100
Both groups applied a transcriptome-wide and antibody-based approach to investigate the topology
of m1A within mRNA. Each protocol ﬁrst enriches for poly-A RNAs that are subsequently chemically
fragmented to approximately 100 to 150 nucleotides (nts). RNAs containing m1A are then speciﬁcally
enriched using an antibody raised against the modiﬁcation. After immunoprecipitation, the antibody-
bound RNA is retrieved and subjected to a transcriptome-wide RNA sequencing protocol, in order to
identify regions containing m1A. A drawback of this method used in both studies is that the position of
m1A cannot be determined at a nucleotide resolution. Sequencing of anti-m1A enriched RNA fragments
allowed the annotation of "m1A-peaks", which span a region between 55 and 150 nts. Nevertheless, this
approach could identify between 887 and 4151 mRNA transcripts that harbor this modiﬁcation. Addi-
tionally, the authors mapped the methylation at the N1 position of adenine within the 5’-UTR of human
mRNAs and/or in close vicinity (approx. 25 nt up- or downstream) of the start codon.99 On average,
only a single m1A peak is present on a methylated transcript. This typical pattern is also seen in mRNAs
from mice suggesting conservation between humans and rodents.99 This pattern is, however, not con-
served in all eukaryotes. Sequencing of the m1A methylomes from Schizosaccharomyces pombe and S.
cerevisiae revealed a diﬀerent proﬁle. Within these organisms methylation is mostly found within the
ORF of mRNAs, whereas the ﬂanking UTRs display a lower abundance.99
Them1A-methyltransferase(s) for mRNA has not been identiﬁed yet. So far, the potential candidates are
enzymes that have been shown to methylate ncRNAs such as tRNA or rRNA.101, 102 The transcriptome-
wide analysis of m1A could not reveal a consensus sequence that could narrow down potential can-
didates. The data provided from the two studies could show that a prerequisite for methylation are
GC-rich regions. It has been experimentally demonstrated that the potential enzyme establishing m1A
utilizes S-adenosyl-methionine (SAM) as methyl donor for the methylation reaction.99 Interestingly, a
potential demethylase has already been identiﬁed that can revert the reaction. This is an interesting
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feature as modiﬁcations such as pseudouridylation, cytosine methylation and deamination of adenine
have so far been reported to be permanent marks. ALKBH3 is the enzyme responsible for the demethy-
lation of m1A and is a member of the AlkB protein family and most likely utilizes an oxidation reaction
to remove the methyl-group as already described for other RNA demethylases (see 1.5.1.1). A knock-out
cell line of this demethylase has revealed numerous m1A peaks that are normally removed within wild
type cells. This in return suggests some sort of speciﬁcity as only certain methylation sites/transcripts
are targeted by the protein.
The fact that m1A is a reversible modiﬁcation and present in the 5’-UTR of mammals suggest that this
methylated adenosine could be a regulatory element involved in diﬀerent biological pathways. It has
been shown by the two sequencing studies that the m1A-methylation patterns respond to diﬀerent
stress stimuli such as heat shock, serum/glucose-starvation and oxidative-stress. This suggests that the
methylation proﬁle is diﬀerentially regulated during normal and stressed conditions. The direct biolog-
ical eﬀects of m1A have yet to be investigated. On a molecular level, this base modiﬁcation interrupts
theWatson-Crick base pairing interface and generates a positive charge at the N1 position under physio-
logical conditions.103 This modiﬁcation can therefore facilitate the remodeling of RNA structures, which
has already been demonstrated in tRNAs.104, 105 This in return could then lead to a biological response.
It is also imaginable that both the positive charge and the methyl group could be a potential binding
substrate for certain proteins (see 1.4.3) or repel others that would bind the RNA in an unmethylated
state. Future investigation will be needed to explore all the proteins that establish, read and modulate
this type of methylation and the biological function they promote.
1.2.5 N6-methyladenosine
The most prevalent internal modiﬁcation found within mRNA is m6A. Using a quantitative liquid chro-
matography - mass spectrometry approach, it has been shown that this modiﬁcation contributes to 0.5
to 1% of the total adenosine pool incorporated into mRNA.106, 107 The discovery that m6A is such an
abundant mRNA modiﬁcation lead to a renaissance in the ﬁeld of RNA modiﬁcations. Investigations on
this adenosine methylation also coined the term of the epitranscriptome. Due to its importance in the
ﬁeld, the next chapters discuss several points such as the topology, the biological consequence and the
proteins that establish, remove and bind to this modiﬁcation.
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1.3 Topology of m6A within mRNA
The presence of m6A in RNA has been known since the nineteen-ﬁfties and -sixties.108, 109 This modiﬁ-
cation hasmostly been detected in diﬀerent ncRNA species such as tRNAs, small nuclear RNAs (snRNAs)
and rRNAs.110 Studies conducted several years later could show thatm6A is also present inmRNAs.111–114
However, analysis on the distribution of this modiﬁcation was limited due to the lack of appropriate
methods. Until recently, the only known messenger that has been shown to harbor m6Aand which
could be biochemically validated was the bovine mRNA encoding for prolactin.115
In 2013, a ﬁrst method was developed to map the presence of m6A on a transcriptome-wide scale.40,41
The protocol ﬁrst utilizes an anti-m6A antibody to enrich methylated RNA fragments of about 100 nts.
Next, the antibody-bound RNA is retrieved and then submitted to high throughput sequencing to iden-
tify m6A-peaks within mRNAs (similar to the approach used to mapm1A, see 1.2.4). The combination of
immunoprecipitation and RNA sequencing has been termed m6A-seq and allowed the identiﬁcation of
m6A in transcripts derived from more than 7000 human and 3400 mice genes. S. cerevisiae and Ara-
bidopsis thaliana are two other model organisms whose m6A-proﬁle has been investigated using the
same antibody-based approach. A total of approximately 1200 methylated mRNAs could be identiﬁed
for yeast whereas 6300 transcripts were found to be methylated in A. thaliana.116, 117 All transcriptome-
wide studies could clearly demonstrate that the presence of m6A in mRNA is a common theme con-
served from lower to higher eukaryotes. Due to the low resolution of these transcriptome-wide stud-
ies, eﬀorts have beenmade to improve this antibody-based approach. By cross-linking them6A-speciﬁc
antibody with the RNA via UV irradiation either induces point mutations (C to T transitions) or produces
truncations during the reverse transcription reaction.118 These signatures allow to pin-point the exact
location of the methylated adenosine within an RNA.
The fact that a great portion of coding transcripts aremethylated suggest that m6A is an abundantmod-
iﬁcation. Strikingly, an average mRNA transcript harbors 3 to 5 m6A-nucleotides.41, 112 This makes m6A
a more prominent mRNA modiﬁcation than the m7G-cap that is a typical mRNA hallmark. Sequenc-
ing data from human and mice revealed that m6A could be found around the transcription start (TSS),
5’-UTR, ORF and 3’-UTR. Subsequent normalization of the data to a"standardized" mRNA could show
that the distribution of this methylated adenosine is not stochastic. Peaks of m6A were highly enriched
around the stop codon andwithin the 3’-UTR (Fig.1.2).40,41 A similar enrichment pattern around the stop
codon has been observed in yeast as well. However, within yeast m6A-methylation is only present dur-
ing meiosis and not present during its vegetative state.116, 119 In plants an additional enrichment around
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the start codon is observed.117 In certain mRNA transcripts, a m6A derivative can be found in close
proximity of the methyl-cap (1 or 2 nts away) that additionally carries a methylation at the 2’OH of the
ribose. This modiﬁcation is, however, established by a diﬀerent machinery than the one catalyzing the
formation of m6A within the internal sequence of the mRNA.120 Therefore, this derivative represents
an independent modiﬁcation with distinct function(s).
Methylation at the N6-position of adenosine does not occur at random but within a degenerated con-
sensus sequence. The sequence that is recognized by the m6A-methyltransferase complex is RRACH
(A = methylated A; R = purine; H = A, C, or U).40,41 Even though this sequence is not very well deﬁned
and can be found throughout the whole messenger, only methylation sites present in the 3’-portion of
mRNAs are readily modiﬁed. The underlining mechanism on how only these sites are recognized and
preferably methylated is currently debated. The absence of an exact methylation sequence and the fact
that not all potential sites are methylated indicate that other factors such as RNA structure or the cou-
pling to a certain biological process might be needed for targeting of the responsible methyltransferase
to these site.
Figure 1.2 Distribution of m6A within mRNA Normalizing m6A-sequencing data to a model mRNA reveals that the most
methyled adenosines are enriched in close vicinity of the stop codon. This enrichment spans a region of approximately 200
nt up- and down stream of the stop codon (ﬁgure adapted from Dominissini et al.41)
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1.4 Molecular and biological impact of m6A in mRNAs
After identifying N6-methyladenosine as one of the most abundant internal mRNAmodiﬁcations found
in humans, questions have arose concerning the impact of this methylated base within cells. Even
though the ﬁeld onm6A has only been revived in 2012, some ground breaking work has been conducted
linking m6A methylation to diﬀerent biological pathways. The next sections are a non-exhaustive list of
some important m6A-dependent mechanisms that have an inﬂuence on several cellular processes.
1.4.1 m7G-independent translation promoted by m6A
The abundance of m6A within the 5’-UTR has been reported to be minor compared to the 3’ region of
a mRNA transcript (see 1.3). Nevertheless, two recent studies could show that even though less fre-
quently deposited in the 5’-UTR the presence of this modiﬁcation can have a signiﬁcant cellular impact.
These reports demonstrate that a single m6A within the 5’-UTR can promote cap-independent transla-
tion.121, 122 How canm6A facilitate translation in a cap independent manner? Meyer et al. could demon-
strate that eIF3 can bind directly to methylated adenosines. As a consequence of this interaction, eIF3
can then recruit the 43S complex to the methylated 5’-UTR of the transcript and initiate translation.122
Interestingly, the same group gathered some evidence for the physiological importance of this mecha-
nism in the cell. Upon heat shock, cap-dependent translation is down regulated for most mRNAs within
a cell.123 The expression of a protein termed Heat-shock protein 70 (Hsp70) is normally induced by this
stimulus and is translated in a cap-independent fashion.124 Hsp70 functions as a chaperon and is thought
to promote the proper folding of proteins during heat shock.125 The mRNA of Hsp70 contains an m6A
within its 5’-UTR and translation of this transcript is methylation dependent.122 In addition to Hsp70,
other mRNAs are methylated at their 5’-UTRs during heat-shock. This observation was conﬁrmed by
Zhou and colleagues, who demonstrated the de novomethylation of 5’-UTRs of diﬀerent mRNAs during
this type of stress.121 Taken together, these studies provide an indication that m6A-methylation could
be a vital mechanism to guarantee that translation of a subset of mRNAs during heat shock.
1.4.2 m6A switch
Initial studies could show that m6A does not perturb the Watson-Crick interface and, thus, does not
alter classical base pairing.126 Nevertheless, m6A has been shown to inﬂuence RNA structure. A mech-
anism termed m6A-switch regulates the binding of a nuclear protein termed heterogeneous nuclear
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ribonucleoprotein C (HNRNPC).127 Local hairpin foldings within mRNAs containing both a m6A- and a
HNRNPC binding site are normally not accessible for the RNA binding protein. Methylation of the hair-
pin reorganizes the structure and allows the binding of HNRNPC. This in return inﬂuences splicing of
the transcript harboring the methylated hairpin. The m6A status of the RNA can be reverted through
specialized enzymes (see 1.5.1.1). The removal of the methylation from the RNA allows it to fold back
to its default state and, again, prevents the binding of HNRNPC. This capability of the RNA to undergo
either an accessible or inaccessible state dependent on the presence or absence of m6A, deﬁnes the
switching character of this phenomenon.
1.4.3 m6A recognition by the YTH domain family - translating m6A into function
Several ideas have been proposed on how a single methyl group at the N6 position of an adenine can
be translated into a molecular or cellular response. One concept postulates that upon methylation, the
binding of diﬀerent RNA binding proteins is prevented either directly or by modulating the surround-
ing RNA structure, as discussed in the previous section. Another interesting concept was proposed by
Dominissini and colleagues. They hypothesized that certain proteins might exist with binding proper-
ties speciﬁc for m6A.41 Upon binding, these proteins could then induce a down-stream process that
results in a molecular/cellular eﬀect. These "reader" proteins would, therefore, function as translators
of the modiﬁcations they bind. This concept resembles a similar mechanism found within proteins that
eﬃciently bind DNA containing 5-methylcytosine (e.g. MeCP2).128 RNA pull-down experiments using
m6A-methylated RNA were conducted, coupled with mass spectrometry, to ﬁnd proteins with binding
properties speciﬁc for this modiﬁcation.41 Within these experiments, the YTH domain family (YTHDF)
members YTHDF2 and YTHDF3 were identiﬁed to bind the methylated RNA but not the unmethylated
control.
As indicated by their name, both proteins harbor a domain that has been termed the YT521-B homology
(YTH) domain. Early assumptions assigned the m6A-binding ability to this protein domain, since both
YTHDF2 and YTHDF3 only have this domain in common. Structural analysis of the founding member of
this protein family YT521-B (also known as YTH domain containing protein 1 (YTHDC1)) and functional
analysis of YTHDF2 could provide experimental evidence that the YTH domain indeed binds speciﬁcally
to m6A.129–131 To date, the human YTH family consists of ﬁve members: YTHDF1-3, YTHDC1 and YTHDC2.
Homologs of these proteins have been found throughout diﬀerent eukarya, ranging from complex or-
ganisms such as humans, rodents and insects down to simple representatives such as Hydra vulgaris
and yeast.130 So far, only the human YTH proteins YTHDF1, YTHDF2 and YTHDC1 have been shown to
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functionally associate with m6A. The next sections brieﬂy summarize the functional roles of these RNA
binding proteins.
1.4.3.1 YTHDF2
As one of two YTH proteins identiﬁed in the initial RNA-pulldown experiment conducted by Dominissini
et al., this protein has provided the ﬁrst insight on which biological functions m6A can promote.41
YTHDF2 is mostly localized within the cytoplasm where it encounters and binds methylated mRNAs.
After binding, YTHDF2 destabilizes the transcript by localizing the RNA into a sub-cytoplasmic structure
termed processing-bodies (P-bodies).129 P-bodies are cytoplasmic foci in which mRNAs can either be
stored or degraded.132, 133 The overall protein organization of YTHDF2 can be divided into two functional
parts. The N-terminal region of this protein is proline-, glutamine- and asparagine-rich (P/Q/N-rich) and
ismost likely responsible for P-body localization.129 The C-terminal half of YTHDF2 bears the YTH domain
and was shown to eﬃciently enrich m6A-methylated mRNA. This study provided ﬁrst direct evidence
for a YTH domain-m6A interaction. Taken together, in the cytoplasmm6A can function as amRNA desta-
bilization signal that is promoted by YTHDF2. This interaction can directly regulate the half-life of the
mRNA and the population size of the translatable transcripts. By inﬂuencing the translatable pool, this
in return has an inﬂuence on the number of mRNAs that can be associated with polysomes (Fig. 1.3).
Figure 1.3 YTHDF2 destabilizes m6A-methylated mRNAs and inﬂuences their half-life After transcription, m6A methylation
and mRNA-processing/transport, mRNAs can either engage in translation or can be bound by YTHDF2. This YTH protein inter-
acts with methylated mRNA via its YTH-domain and localizes the bound transcript into P-bodies. This transport is facilitated
by the P/Q/N-rich domain of the protein. Within these foci, cytoplasmic RNAs can be either stored or degraded. The latter
eﬀect results in a shorter half-life of mRNAs targeted by YTHDF2. Figure adapted fromWang2014a129
13
1. Introduction
Additionally to this ﬁnding, some evidence has been collected that YTHDF2 can help promote cap-
independent translation upon heat shock. A recent study showed that YTHDF2 can shuttle into the
nucleus under stress conditions.121 Within this compartment, it is assumed that YTHDF2 binds to m6A
present in the 5’-UTR of (pre-)mRNAs. This interaction protects these methylated sites from demethy-
lation that would otherwise occur within unstressed cells, as YTHDF2 is normally not present in the
nucleus. After export into the cytoplasm, the methylated 5’-UTR can engage in cap-independent trans-
lation that is promoted through the interaction of eIF3 with the methylated adenosine that was (pre-
sumably) protected by nuclear YTHDF2 (see 1.4.1).
1.4.3.2 YTHDF1
YTHDF1 is the second YTH domain containing protein whose function within the cell was investigated
in more detail. Like YTHDF2, YTHDF1 is localized within the cytoplasm and interacts with mRNAs har-
boring m6A-methylated 3’-UTRs. This binding is carried-out with the YTH domain that resides within
the C-terminal half of the protein.134 In contrast to YTHDF2, the N-terminal portion of YTHDF1 does
not destabilize the bound transcripts, but rather promotes their translation (Fig. 1.4).134 This molecular
eﬀect is facilitated by YTHDF1 through the interaction with eukaryotic initiation factors and in particular
with eIF3. However, this 3’-UTR dependent induction of translation seems to be a diﬀerent mechanism
than the one promoted solely by eIF3 binding to the 5’-UTR during heat shock. The process of the for-
mer is not completely investigated, whereas the latter case relies on the direct interaction betweenm6A
and eIF3 (see 1.4.1). Another vital requirement for the YTHDF1-dependent mechanism seems to be the
formation of a closed looped mRNA structure prior to translation, which is promoted by eIF4G.134, 135
This conclusion was made byWang et al. through experiments using internal ribosome entry site (IRES)
reporters that either omitted or required eIF4G for eﬃcient enhancement of translation promoted by
YTHDF1.134 Translation is a multi-stage process involving several steps such as assembly of the 43S com-
plex on the mRNA, AUG scanning and initiation and elongation of translation.135 The current model for
YTHDF1-promoted translation is that this protein interacts with initiation factors to increase translation
eﬃciency of target mRNAs. Translation eﬃciency is deﬁned as the quotient of protein synthesis and
mRNA abundance. Thus, YTHDF1 enhances the protein out-put of methylated transcripts compared to
non-methylated ones without the necessity of increasing transcription.
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Figure 1.4 YTHDF1 promotes translation in a m6A-dependent manner Messenger transcripts that have experienced m6A
methylation can undergo YTHDF1-promoted translation. For this process, YTHDF1 binds to the methylated 3’-UTR of mRNAs
and interacts with translation initiation factors such as the eIF3 complex. This protein-protein interaction is vital to enhance
translation eﬃciency resulting in an increase of protein synthesis while the abundance of target mRNAs remains the same.
Figure adapted from the graphical abstract of Wang et al.2015134
A central question that can be asked is: can the mechanisms promoted by YTHDF1 and YTHDF2 both
coexist within the cell? If they are both spatiotemporally present within a cell, which one is more dom-
inant or how are theses two processes regulated? Wang and colleagues demonstrated that targets
shared by both proteins can experience enhanced translation (YTHDF1) and display shorter half-lifes
(YTHDF2).134 Shared target mRNAs of both YTH proteins are bound at diﬀerent time points during their
life cycle. These transcripts are preferably ﬁrst bound by YTHDF1, resulting in higher protein synthesis,
before they are bound by YTHDF2, targeting them for storage or degradation in P-bodies. This tempo-
ral separation of both m6A-promoted mechanisms allow a complex regulation of both translation and
mRNA stability. With such a regulation network, one could imagine that such processes enable a quick
response to diﬀerent cellular or molecular stimuli that occur during various events such as stem cell
diﬀerentiation, gametogenesis and embryonic development.
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1.4.3.3 YTHDC1
YTHDC1 (also known as YT521-B) was the founding member of the YTH-domain protein family. Before
the association of the YTH-domain with m6A-binding, studies indicated an involvement of this protein
in alternative splicing.136 This protein was found in subnuclear foci termed YT-bodies.136–138 These foci
are claimed to represent so-called transcription centers and are in close proximity to other nuclear
structures such as coiled bodies and nuclear speckles.137 Through structural analysis it has been demon-
strated that the YTH-domain that resides in the C-terminus of YTHDC1 can eﬃciently bindm6A facilitated
by the highly conserved tryptophan residues at the amino acid positions 380 and 431.130, 131
Recently, a mechanismwas reported in which YTHDC1 can regulate alternative splicing in am6A- depen-
dent fashion (Fig. 1.5).139 With its N-terminal half, YTHDC1 can bind to the serine/arginine-rich splicing
factors (SRSF) SRSF3 and SRSF10. The binding sites of all three proteins have been demonstrated to re-
side within the boundaries of 5’- and 3’-splice sites. In addition to this, m6A methylation peaks can also
be found within these regions, indicating a possible interconnection between mRNA methylation and
splicing. The formation of a SRSF3/YTHDC1 complex promotes exon inclusion. This is facilitated through
the binding of YTHDC1 to a methylated splice site which in return allows SRSF3 to enforce the inclusion
of the targeted exon.
Interestingly, binding of YTHDC1 to SRSF10 results in an antagonistic eﬀect. The formation of this hetero-
dimeric complex results in the suppression of the splicing reaction promoted by SRSF10 alone (exon skip-
ping). Not only does YTHDC1 inﬂuence the function of both SRSFs, but also their localization. While the
import of SRSF3 into nuclear speckles is stimulated by YTHDC1, the opposite is observed for SRSF10. This
import into nuclear speckles is another indication that YTHDC1 is involved in splicing, as many splicing
factors (e.g. various SRSFs) are enriched in these subnuclear structures.140–143 The underlining mecha-
nism on how this selective import is facilitated remains enigmatic. This YTH-protein is the third repre-
sentative that clearly underlines that "reader"-proteins are essential to translate the m6A-methylation
into a speciﬁc function but are not the only mechanism on how this modiﬁcation can inﬂuence cellu-
lar physiology. Further challenges within the ﬁeld will be to identify more proteins with maybe novel
m6A-binding domains and to functionally validate these.
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Figure 1.5 YTHDC1’s involvement in alternative splicingm6A methylation sites in close proximity of a potential splice site can
be bound by the nuclear YTH protein YTHDC1 that forms a complex with SRSF3. The splicing factor binds its own sequence
located near a methylated m6A-site. Binding of this complex to both sites (m6Amethylation and SRSF3-binding) facilitates the
inclusion of the methylated exon in the spliced transcript. This process is antagonized by a diﬀerent splicing factor termed
SRSF10. This protein leads to exon-skipping upon binding to its sequence of an unmethylated transcript and/or blocking the
binding of the YTHDC1/SRSF3 complex. Figure adapted from the graphical abstract of Xiao et al.2016139
1.5 Proteins shaping the m6A methylome
1.5.1 m6A-demethylases - modulators of the m6A landscape
Even though m6A has been known to be present within mRNA since the sixties, the ﬁeld recently has
attracted great attention through the discovery of specialized enzymes that can revert the methylation
at the N6-position of adenine. Investigations conducted on these "erasers" were, together with ad-
vances in mapping of m6A in diﬀerent RNAs, the driving force for the renaissance of the m6A ﬁeld. So
far, two proteins have been identiﬁed that can demethylate RNAs containing m6A. This ﬁnding suggests
that m6A in addition to other RNA modiﬁcations is reversible. This resembles several processes found
within the ﬁeld of epigenetics, for instance DNA-methylation or histone modiﬁcations.144
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1.5.1.1 Fat Mass and Obesity-Associated Protein (FTO)
The fatmass andobesity-associated protein (FTO)was theﬁrst enzyme identiﬁedwithm6A-demethylase
activity.106 It was, however, ﬁrst presumed that this protein is a DNA/RNA repair enzyme, since FTO has
been shown to be related to the AlkB protein family and is able to oxidize 3-methylthymine in single-
stranded DNA and 3-methyluracil in ssRNA.145–148 As suggested by its name, certain human variants of
FTO have been associated with an increased body-mass-index (BMI).149, 150 Strikingly, genetic studies
carried out in Fto knock-out (Fto-/-) mice have demonstrated that the inactivation of the Fto-gene leads
to a reverse phenotype, the reduction of total body mass.151 A proposed hypothesis is that the lack
of Fto in the mice leads to a higher energy expenditure. This in return is the cause for the observed
reduction in body weight. Some evidence for this hypothesis has been provided by a study indicating
that FTO might function as a nutrient sensor that inﬂuences amino acid levels within the cell.152 The
hypothesis of the involvement of the RNA demethylase in energy homeostasis is further supported by
the observation that FTO is essential for adipogenesis via the regulation of mRNA splicing153
FTO is predominantly found within the nucleus as a putative nuclear localization signal (NLS) within its
N-terminus has been predicted in silico but has not been functionally validated so far.146, 154 Diﬀerent
reports have, however, indicated that FTO can shuttle between the nucleus and the cytoplasm.152, 155 It
has yet to be determined what the underlining mechanism is and what the biological relevance of this
traﬃcking between compartments is. Within the nucleus, FTO localizes into nuclear speckles and thus
is present in the same nuclear sub-compartment as YTHDC1 (see 1.4.3.3) and themethyltransferase that
establishes m6A within mRNAs (see 1.5.2).
FTO utilizes oxygen, α-ketoglutarate and non-haem bound FeII to catalyze the oxidation of m6A. This
reaction resembles that of Ten-eleven translocation (TET) proteins that convert m5C in DNA into cyto-
sine.156–159 Another similarity between this RNA- and the DNA-demethylases is that the oxidation of the
methylated base is a step-wise process.160 FTO has been shown to convert m6A ﬁrst into N6-hydroxy
methyladenosine (hm6A) and then N6-formyladenosine (f6A). The latter can then be hydrolyzed by the
surrounding water in the cell to give rise to an unmethylated adenosine (Fig.1.6).161
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Figure 1.6 Purposed demethylation reaction of m6A catalyzed by FTO The m6A demethylase FTO removes the methyl-group
on the N6 position of adenosine in a step-wise fashion. First, oxygen and α-ketoglutarate are utilized to convert m6A into
N6-hydroxymethyl adenosine (hm6A). This product can spontaneously react to adenosine by releasing a formyl group. Hm6A
can be further oxidized to N6-formyladenosine (f6A), during a second reaction round. This product can then be hydrolyzed,
thereby releasing formic acid that in return gives rise to an unmethylated adenosine.
1.5.1.2 Alkylation repair homolog 5 (ALKBH5)
The Alkylation repair homolog 5 (ALKBH5) is the second representative of m6A-demethylases that has
been identiﬁed.107 This protein has a similar catalytic activity as FTO on substrates containing m6A.
ALKBH5 requires for its oxidation reaction the cofactors α-ketoglutarate, oxygen and iron, which are
identical to the ones utilized by FTO.162, 163 Even though both proteins are dependent on the same cofac-
tors for their catalysis and generate the same end-product, so far it seems that ALKBH5 cannot generate
the same intermediates as observed for FTO. This could indicate that both demethylases might pursue
diﬀerent routes for demethylation or the reaction eﬃciency between both proteins varies.164, 165
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Another diﬀerence between ALKBH5 and FTO are the phenotypes observed in knock-out mice. Primar-
ily spermatogenesis was eﬀected upon deletion of the ﬁrst exon of Alkbh5, resulting in viable but sterile
male mice. Alkbh5 does not only impact the morphology of the resulting spermatozoa, but also inﬂu-
ences the architecture of the testis. ALKBH5 co-localizes to nuclear speckles and therefore can be found
in the same sub-nuclear structure as FTO and other proteins that interact with m6A. An observed cell
physiological consequence of the absence of ALKBH5 is the accelerated export of mRNAs from the nu-
cleus.107 Theunderlyingmechanism that interconnects the demethylation reaction catalyzed byALKBH5
and mRNA export has not been investigated so far. However, an involvement of reader proteins such as
members of the YTH protein family could be hypothesized.
Another aspect that needs to be addressedwithin the ﬁeld is that it is not clear on how the demethylases
choose their substrate. Are other protein factors necessary or certain RNA structures? Results from
these investigations could then in return shed light on how deﬁciencies in demethylation are translated
into so complex and diverse phenotypes.
1.5.2 METTL3-METTL14 complex - the m6A-writer
First experimental approaches to identify and characterize the protein or proteins in humans that es-
tablish the methylation of adenine within mRNA were conducted by Bokar and colleagues in the mid-
nineties.166, 167 The outcome of these experiments pointed out that the human m6A-methyltransferase
is a high molecular weight complex and is build-up by two distinct components. These subunits can be
separated under non-denaturing conditions and were termed MT-A and MT-B that posses molecular
weights of 200 kDa and 875 kDa respectively.167 It was suggested that the MT-B portion of the complex
possesses nucleic acid aﬃnity, as it can be puriﬁed using single stranded DNA coupled to an agarosema-
trix. Beside this experiment, no further characterization of the complex was conducted. For the MT-A
subunit it could be shown that this component of the methyltransferase contains a 70 kDa protein that
can bind SAM. This protein was therefore named MT-A70, which would latter be renamed to METTL3
(methyltransferase-like protein 3).
BesidesMETTL3, additional components of the humanm6A-methyltransferase complexwere described
by independent groups. METTL14, another member of the METTL protein family, was found to inter-
act directly with METTL3.168, 169 Both proteins together form a stable heterodimer with a calculated
molecular weight of 120 kDa. In a two dimensional native/SDS-PAGE experiment a molecular weight of
approximately 200 kDa could be determined. This ﬁnding suggests that the METTL3/METTL14 dimer
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(METTL3/14) could be the MT-A component of the methyltransferase complex initially described by
Bokar et al.167
The METTL3/14 complex is predominantly localized within nuclear speckles. Therefore, the m6A-writer
and both demethylases are present and carry out their function in the same sub-nuclear compartment.
How the activities of the writer and erasers are modulated within the same space is still under inves-
tigation. Insight into the regulation mechanism could also shed light on how the selectivity of the
methyltransferase is established or how certain sites are protected or abolished. For the localization
into nuclear speckles, theMETTL3/14 requires the interaction of theWilms’ tumor 1-associating protein
(WTAP). This protein has been shown to interact directly with METTL3.168, 170 Depletion of the protein
results in the improper import of the METTL3/14 into nuclear speckles and a diﬀuse distribution within
the nucleoplasm. This mislocation is most likely also responsible for the observed reduction of endoge-
nous m6A-levels induced upon knock-down of WTAP. However, a modulating eﬀect on the catalysis of
METTL3/14 promoted by WTAP has not been extensively investigated in vitro and cannot be ruled out.
The vast majority of studies have concentrated on the biological impact of METTL3. It has been, for
instance, demonstrated by several publications that METTL3 and its homologs are essential for survival
of multicellular organisms such as mice, Drosophila and Arabidopsis.171–173 Within all these species,
embryos fail to develop to full maturity. Some insight to the molecular implications of METTL3 during
embryonic development has been recently provided to some detail in mice.169, 171, 174 The ﬁrst two pub-
lished studies conducted inmouse embryonic stem cells (mESC), presented rather contradictory results.
Whereas Wang et al. demonstrated that upon knock-down of METTL3 and METTL14 lead to a reduced
ability of self-renewal, Batista and colleagues provided results that suggested the opposite.169, 174 In
their study, mESC METTL3-/- cells displayed a complete block of diﬀerentiation and display enhanced
self-renewal capacity.
The study conducted by Geula et al. has to some extent resolved these at ﬁrst glance controversy obser-
vations.171 During early development, pluripotent mESCs can posses two molecular distinct states. The
ﬁrst one is the so-called "naïve" state in which the stem cells posses an unbiased developmental poten-
tial. Within the second "primed" state, the cells are poised to initiate lineage speciﬁc programs.175, 176
The Geula study could show that within naïve mESCs, mRNAs encoding for pluripotency factors are pre-
dominant and m6A-methylated, which has a negative impact on mRNA half life. Depletion of METTL3
within this state leads to an upregulation of these factors, by increasing their stability. The higher abun-
dance of pluripotency factors leads to a so-called hyper-naïve phenotype (Fig. 1.7). A hallmark of this
state is a poor diﬀerentiation potential of the cells, which was demonstrated in the study by teratoma
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formation assays. This incapability to initiate diﬀerentiation is the cause for the observed lethality of
the embryo shortly after implantation.
Figure 1.7 METTL3 is essential for the balancing of developmental factors during diﬀerent pluripotent cell states Depending
on the state in which METTL3 is depleted, cells can either enter a hyper-naïve or highly committed diﬀerentiation state. This
is the result of reduced m6A-methylation, which in return stabilizes the highly abundant mRNAs encoding for pluripotency
maintenance factors in the naïve or dominating diﬀerentiation-factors in the primed state. Figure adapted from Zhao and
He.177
Adiﬀerent phenotype is observedwhenMETTL3 is depleted frompluripotent cells that posses a "primed"
state. ThesemESCs normally display a high abundance ofmRNAs encoding for lineage-commitment fac-
tors. These are as well methylated like the pluripotency factormRNAs observed in the naïve phenotype.
Abolishing m6A by knocking-down METTL3 leads to an accelerated diﬀerentiation that destabilizes the
primed state and ultimately leads to cell death (Fig. 1.7). From the Geula study, it seems evident that
METTL3 plays a crucial role to maintain a transcriptional balance during diﬀerent phases of embryonic
development. By manipulating the abundance of METTL3 at certain stages leads to a disruption of this
balance and can therefore lead to the diﬀerent observed phenotypes.
Studies conducted in other organisms could link METTL3 to other developmental processes other than
embryonic development. For example oogenesis in female Drosophilas is greatly impaired when these
ﬂies carry a hypomorphic mutation of IME4, the ﬂy homolog of METTL3.172 Multicellular organisms
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are not the only ones that display defects in complex biological processes such as those previously de-
scribed. For S. cerevisiae, it has been demonstrated that thesemicroorganisms rely onm6A-methylation
for the proper execution of meiosis. Interestingly, this modiﬁcation is completely absent during the veg-
etative life-cycle of the cell and accumulates during the transition into the sexual phase.116, 119, 178, 179These
ﬁndings clearly highlight the importance of both themethylation machinery andm6A and their involve-
ment in complex biological processes.
1.6 Aim of the thesis
Compelling evidence has been collected over the last ﬁve years that demonstrate the importance and
impact of m6A on diﬀerent biological processes. At the heart of the various mechanisms inﬂuenced
by this post-transcriptional modiﬁcation lies the methyltransferase machinery. Even though the im-
portance of the METTL3/14 complex has been studied to some detail, several unanswered questions
still remain. For instance, why does the minimal m6A-methyltransferase complex potentially carry two
methyltransferases? Which portion(s) of the complex interacts withWTAP?Which protein domain(s) of
METTL3 andMETTL14 are essential for the formation and stability of the heterodimer? These questions
should be addressed biochemically using recombinant proteins and by recapitulating the methylation
process in vitro. Another aspect investigated in this thesis is how the three known interactors of the
m6A-machinery (METTL3/14 and WTAP) are imported into the nucleus. For this, potential nuclear lo-
calization sequences are ﬁrst predicted using the Eukaryotic Linear Motif resource tool.180, 181 Next, NLS
mutants of the individual proteins should be generated and the impact on protein localization of these
introduced mutations should be analyzed during immunoﬂuorescence experiments.
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2.1 Structure prediction of the human METTL3/14 complex
Since little information on the architecture of the human N6-methyltransferase has been published, we
sought out to characterize the protein complex using diﬀerent biochemical methods. As a ﬁrst step,
the secondary structures of both METTL3 and METTL14 were predicted using the online tool Psipred
(see section 5.2.6.2 and the sections 6.1 and 6.2 in the appendix). The bioinformatic data obtained
using this approach allowed the deﬁnition of structured domains within both METTL proteins (Fig. 2.1).
METTL3 possesses three distinct protein regions that are separated by unstructured segments. The
ﬁrst two regions have to date unknown function. The third domain of METTL3, that resides within the
C-terminus, is the so-calledMT-A70 domain. This domain has been reported to be associatedwith SAM-
binding and catalysis.178, 182 METTL3 posses within the ﬁrst amino acids of this domain a DPPW motif
that is found in other methyltransferases as well and is responsible for the catalytic activity of these
proteins.178, 182
METTL3
METTL14
580389 550
MT-A70
76 2861 34
186 363
MT-A70
4561 87
FAVVMADPPWDIHMELPY
Catalytic motive
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Catalytic motive
Figure 2.1 Schematic representation of METTL3 and METTL14 Structural domains of METTL3 and METTL4 have been deﬁned
using the secondary structure prediction algorithm Psipred (see Fig.6.1 and 6.2 in the appendix). METTL3 is divided into
three distinct domains. The ﬁrst two domains have not been associated with a speciﬁc function, whereas the last structured
region represents the annotated MT-A70 domain. METTL14 also contains this MT-A70 domain that is similar to the one found
in METTL3. The predicted catalytic residues within the MT-A70 domains of both proteins have been highlighted in red. In
addition to the MT-A70 domain, METTL14 possesses a second structured region at its N-terminus with unknown function.
Numbers indicated above each protein display the amino acid position of the domain boundaries.
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METTL14 also possesses a MT-A70 domain, which is located within the center of the protein. However,
distinct fromMETTL3, this methyltransferase-like protein harbors a slightly diﬀerent catalytic motif. The
domain harbors an EPPL- and not a DPPW-tetrad. It has not been determined yet, if the substitutions
at the ﬁrst and fourth position of this catalytic motif has any functional impact on the assembled com-
plex or not. Besides the MT-A70, METTL14 has a structured N-terminus with unknown function. These
structure predictions were essential in order to design full-length and truncation constructs that have
the aim to provide structural and functional information of the METTL3/14 dimer.
2.2 Puriﬁcation and functional analysis of the human METTL3/14 complex
The group that ﬁrst puriﬁed the METTL3/14 complex could demonstrate that this minimal complex is
suﬃcient for the formation of m6A in vitro.168 Subsequent experiments conducted with each subunit
alone demonstrated that of the twoMETTL proteins present in the complex,METTL14 possesses a higher
activity than METTL3. So far, however, it has not yet been tested if METTL14 is the catalytic subunit
within the reconstituted complex. In addition to this, the structural prediction conducted in the previous
section could show diﬀerences in the catalytic motif of both METTL proteins. METTL14 possesses an
EPPL-motif that diverges from the catalytic active DPPW-motif seen in other methyltransferases.178, 182
To address if the EPPL-motif is still functional and to test if METTL14 is the catalytic subunit within the
dimer, a SAM-binding experiment, using the assembled METTL3/14 complex, and a mutational study
were performed. Besides cofactor-binding andmethylation activity, RNA-binding of the binary complex
was also investigated in vitro.
For all these experiments an expression and puriﬁcation system needed to be established in order to
obtain diﬀerent METTL3/14 complexes. In addition to this, a read-out system also had to be set-up that
can eﬃciently monitor the catalytic activity of the diﬀerent methyltransferase complexes during the
mutational analysis.
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2.2.1 Expression and puriﬁcation of human METTL3/14
Full length METTL3 and METTL14 were cloned into a single vector (pFastBac Dual, designed and cloned
by Dr. Nora Treiber, University Regensburg) to guarantee the expression of both proteins in a single
cell. Within this plasmid, only METTL3 was tagged with the Glutathione S-transferase protein (GST).
This construct was utilized to generate a high-titer baculovirus suspension that in return was used to
promote the expression of both METTL proteins in SF21 cells. A GST-pulldown was performed from the
lysates of these infected cells. As displayed by Fig.2.2 A, not only was the GST-tagged METTL3 puriﬁed
with this approach but also the untagged METTL14 protein. This result indicates that both constructs
are capable to form a dimer within insect cells and that a native complex can be isolated from these
cells.
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Figure 2.2 Puriﬁcation of an active GST-METTL3/14 complex from Sf21 cells A) GST-tagged human METTL3 and untagged
human METTL14 were puriﬁed from Sf21 cells infected with a baculovirus construct encoding for both proteins. B) Catalytic
activity of the puriﬁed GST-METTL3/14 complex shown in A) was demonstrated using a m6A in vitromethylation assay, which
utilizes 3H-marked SAM. To demonstrate methylation speciﬁcity, an RNA that either harbored the methylation consensus
sequence GGACU or a variant missing the methylatable adenine was used in the assay. After the methylation reaction, the
RNA was retrieved for activity measurements in a scintillation counter or for a radiographic analysis. C) Shown are the RNA
sequences of the substrates used for the in vitromethylation assay.
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The retrieved protein complex from this small-scale puriﬁcation was split into to two separate setups
to perform a m6A in vitro methylation assay (Fig. 2.2 B). During this assay, the puriﬁed complex was
either incubated with an RNA substrate containing a single m6A-methylation site (GGACU) or with an
RNA that possesses a uracil instead of an adenine within the predictedmethylation sequence (GGUCU).
The latter substrate, therefore, functioned as a negative control during the assay (Fig. 2.2 C).
3H-labeled SAM was used as a cosubstrate in this methylation assay and, thus, made it possible to
assess the methylation activity of the protein complex in a scintillation counter, after removing non-
utillized SAMand retrieving the RNA. The reaction containing them6A-RNA substrate displayed a robust
signal of several thousand counts per minute (c.p.m.). The negative substrate, on the other hand, only
displayed background levels of radioactivity. To validate the scintillation measurement, the RNA from
both methylation reactions was isolated and loaded onto a denaturing gel. After separation, the RNA
was blotted onto a membrane that was afterwards exposed to an X-ray ﬁlm (Fig. 2.2 B, in cooperation
with Dr. Thomas Treiber, University Regensburg). Similarly to the scintillation measurement, only the
RNA containing the RRACH motif displayed a robust signal compared to the negative substrate. These
two experiments indicate that the recombinant METTL-complex puriﬁed from Sf21 cells is active and
can distinguish between a methylatable and non-methylatable substrate. This, therefore, suggests that
a native and active GST-METTL3/METTL14 complex was eﬃciently puriﬁed.
2.2.2 METTL3 can eﬃciently bind SAM within the METTL3/14 dimer
One of the key questions that should be addressed with the puriﬁed protein complex is: why does the
METTL3/14 complex posses two methyltransferases that could be potentially active? As a ﬁrst exper-
iment it should be tested if both proteins in the complex are capable to bind the methyl donor SAM.
For this experiment the GST-tagged METTL3/14 complex was puriﬁed in a similar fashion as described
in the previous section (Fig.2.3 A and see section 2.2.1).
The recombinant complexwas thenpre-incubatedwith 3H-marked SAMbefore conducting a time course
experiment, inwhich theMETTL3/14 complexwas irradiatedwithUV light to cross-link themethyl donor
to one or both METTL proteins. After cross-linking, the proteins from each sample were loaded onto a
SDS-PA gel, in order to separateMETTL3 andMETTL14 from one another. The gel was then subsequently
ﬁxated and incubated in scintillation solution. The treated gel was then dried and exposed to a X-ray
ﬁlm to visualize any cross-link events that have occurred during UV-irradiation (Fig. 2.3 B). Interestingly,
during the time-course of 30min, only a single band can be identiﬁed that gradually intensiﬁes dur-
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ing the experiment. This band possesses a molecular weight of approximately 100 kDa and correlates
to the calculated size of GST-METTL3 (90.8 kDa). This experiment indicates that SAM can be more eﬃ-
ciently cross-linked toMETTL3 than toMETTL14. This in return allows to hypothesize thatMETTL3 could
probably be the only methyl donor-binding subunit within the dimeric complex.
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Figure 2.3 METTL3 can eﬃciently bind SAM within the METTL3/14 complex A) Coomassie gel of batch-puriﬁed GST-
METTL3/14 used for the SAM cross-linking experiment. B) Recombinant GST-METTL3/14 complex was incubated with 3H-
marked SAM and cross-linking of the complex with the cofactor was induced by UV light (254 nm). Irradiation time for the
diﬀerent setups is indicated above the displayed radiogram.
2.2.3 Large-scale puriﬁcation and reﬁnement of the METTL3/14 complex
To further investigate if both or only one of the two METTL proteins is catalytically active, mutant con-
structs should be designed and expressed which should then be tested in an in vitromethylation assay.
Beside this experiment, other experiments such as electrophoretic mobility shift assays (EMSAs; see
2.2.6) or chemical cross-linking and mass spectrometry analysis (CX-MS; see 2.3.3) of the complex re-
quired larger quantities of the dimer, which cannot be achieved by GST-batch puriﬁcation. Not only a
higher yield of recombinant protein should be achieved, but a strategy should also be developed that
allows the removal of contaminants, such as free GST-protein, from the preparation of the complex. Ac-
quiring a homogeneous and highly puriﬁed sample of the complex minimizes artifacts and also allows
to accurately determine the concentration of the dimer. This in return facilitates the possibility to make
quantitative and qualitative comparisons between experiments.
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Sf21 lysates generated from cells infectedwith baculoviruses encoding for theMETTL3/14 complex were
ﬁrst puriﬁed using a GST-trap. Glutathione-eluted proteins were then treated with TEV protease, in or-
der to cleave the GST-tag fromMETTL3 during dialysis (puriﬁcation programwritten and HPLC operated
by Dr. Thomas Treiber, University of Regensburg). A gel ﬁltration was carried out as a ﬁnal step to obtain
the highly puriﬁed human METTL3/14 complex. As assessed in a PA gel (Fig. 2.4 A), the integrity of the
complex is not compromised during the multiple puriﬁcation steps. This indicates that the METTL3/14
complex is quite stable in solution over the time period of two days, in which the dimer is puriﬁed.
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Figure 2.4 HPLC puriﬁcation of the recombinant METTL3/14 complex A) Large-scale puriﬁcation of human METTL3/14 from
infected Sf21 cells. Recombinant protein was puriﬁed using a GST-trap column and by subsequently removing the tag via TEV-
digestion and HPLC gelﬁltration. B) Activity of the puriﬁed and polished METTL3/14 complex was examined in a m6A in vitro
methylation assay using modiﬁed RNA substrates (compare with Fig. 2.2 C).
As this puriﬁcation strategy varies from the one previously used, we next assessed if the reﬁned complex
is still active using the same in vitrom6A-methylation assay as described in section 2.2.1 (Fig. 2.4 B). The
HPLC-puriﬁed and untagged METTL3/14 complex can eﬃciently methylate the adenosine present in a
RRACH sequence context. The negative substrate on the other hand, only displays low activity that are
close to background measurements (data not shown). This leads to the conclusion that the established
puriﬁcation strategy does not have a negative impact on catalysis of the METTL3/14 complex. Addition-
ally, this strategy allows to purify constructs that more closely resemble a complex that is endogenously
present in cells.
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2.2.4 Construction of mutant variants of the METTL3/14 complex
It has been published that the formation of m6A can be suﬃciently catalyzed by METTL14 alone.168
METTL3, on the other hand, did not demonstrate any activity by itself in the experiments conducted in
the same report. However, the activity of each individual subunit has not been investigated within the
context of the dimeric complex. In addition to this, the result obtained from the SAMcross-linking exper-
iment also challenges the view of METTL14 being the catalytic subunit of the mRNA-methyltransferase
complex. Therefore, variants of the METTL3/14 complex were constructed in which either the DPPW-
motif in METTL3 or the EPPL-motif in METTL14 carry point-mutations (Fig. 2.5 A; plasmids designed and
cloned by Dr. Nora Treiber, University Regensburg). Two of the four predicted catalytic residues (shown
in red) that reside within the N-terminus of the MT-A70-domain of both proteins were exchanged for
alanines (shown in blue). These manipulations should allow to test if both proteins are catalytically ac-
tive or not. The resulting mutant constructs were termed METTL3 APPA or METTL14 APPA in order to
clarify which of the two METTLs bear the described substitutions.
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Figure 2.5 Generation of catalytic mutants of METTL3 and METTL14 A) Schematic representation of the MT-A70 domain
of METTL3 and METTL14. The predicted catalytic residues (red) of both wild-type (WT) METTL proteins are located in the N-
terminal region of theMT-A70 domain. The ﬁrst and fourth amino acid of the catalytic motif have been exchanged for alanines
(shown in blue) in order to generate APPA mutants of METTL3 and METTL14. B) Coomassie staining of the recombinant APPA
mutants using the same puriﬁcation strategy as explained in section 2.4. Indicated numbers illustrate the amnio acid position
within the respective protein.
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Both APPA mutants were expressed in Sf21 cells and puriﬁed in a similar fashion as described in sec-
tion 2.2.3. The puriﬁed protein complexes were analyzed on a PA gel to investigate if the introduced
alterations have any impact on the dimerization-capability of both METTL proteins (Fig. 2.5 B). Both
the METTL3 APPA as well as the METTL14 APPA mutant can eﬃciently associate with their appropriate
counterpart and both complex variants can be readily puriﬁed.
2.2.5 Methyltransferase activity relies solely on the MT-A70 domain of METTL3
After purifying the diﬀerent mutant variants of the METTL3/14 complex, the catalytic activity of these
constructs should be examined during an in vitromethylation assay (Fig. 2.6).
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Figure 2.6 METTL3 is the catalytic subunit of the human METTL3/14 complex The catalytic activity of the three METTL3/14
complex variants (WT, METTL3 APPA and METTL14 APPA) were examined in an in vitromethylation assay. Activities were ﬁrst
normalized to the RNA amount isolated from each setup after themethylation reaction. Afterwards, the activities of the APPA
mutants were normalized to the wild type signal.
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Both the wild type and METTL14 APPA complex display a robust activity. The reduced activity observed
for the METTL14 APPA construct, when compared to the wild type, is likely the result of utilizing un-
equal amounts of protein in the assay and not from the introduced mutation. The METTL3/14 complex
bearing two point mutations within METTL3 shows no signiﬁcant activity in comparison to the other
two versions of the dimer. This results demonstrates that the DPPW-motif of METTL3 is essential for
m6A-formation in the context of the METTL3/14 dimer.
2.2.6 The METTL3/14 complex displays no clear substrate-binding speciﬁcity
Methylation activity of the METTL3/14 complex relies on the binding of the dimer to its RNA substrate.
Electrophoretic mobility shift assays (EMSAs) were conducted to determine and calculate the dissoci-
ation constant of the methyltransferase (Fig. 2.7 A). Diﬀerent concentrations of wild type METTL3/14
were incubatedwith a 32P-labeled RNA substrate, harboring the samemethylation sequence as used for
the in vitromethylation assays, as described in the previous sections 2.2.3 and 2.2.5. Within the tested
concentration range and under standard EMSA buﬀer conditions (including yeast tRNA and heparin),
no shift of the protein complex can be observed. A prominent shift, on the other hand, is displayed by
the setup that includes the methyltransferase but omits both EMSA buﬀer additives used in the other
samples (lane 5).
These observations lead to experiments that should examine which of the two components blocks the
binding of the METTL3/14 complex to its methylation substrate. First, setups containing the recombi-
nant dimer and an increasing amount of yeast tRNAwere analyzed in an EMSA (Fig. 2.7 B). The indicated
shift observed in the reaction containing no tRNA (lane 2) is signiﬁcantly reduced when including tRNA
in the EMSA buﬀer (lane 3). Increasing the concentration of tRNA rapidly abolishes the shift (lanes 3 -
7) and above a tRNA-threshold of 250 µg/ml, no shift can be detected (lanes 8 - 9). Next, the impact
of heparin on the observed RNA-binding of METTL3/14 was examined (Fig. 2.7 C). Similar to the exper-
iment conducted with yeast tRNA, increasing amounts of heparin was added to each setup containing
the EMSA incubation buﬀer and the METTL3/14 complex (lanes 3 - 8). In the setup omitting heparin
(lane 2), a shift with three distinct bands can be observed. The upper two bands lose intensity that
correlates with higher concentrations of the polyanion (lanes 6 - 8).
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Figure 2.7 The METTL3/14 complex binds unspeciﬁcally to polyanions A) An electrophoretic mobility shift assay was per-
formed with various concentrations of the METTL3/14 complex and under two diﬀerent buﬀer conditions. B) RNA substrate-
binding of theMETTL3/14 complexwas challenged using various concentrations of yeast t-RNAs in an EMSA. C) EMSA analyzing
the RNA-binding ofMETTL3/14when incubatedwith diﬀerent concentrations of heparin. D) RecombinantMETTL3/14 complex
was incubated with diﬀerent nucleic acid substrates and binding was assessed in an EMSA.
In a ﬁnal experiment, diﬀerent nucleic acid substrates containing a single RRACH motif were used. The
recombinantMETTL3/14 complexwas either incubatedwith a RNA-, DNA-substrate or a hybrid that con-
tained a RNA RRACHmotif ﬂanked by DNA sequences (Fig. 2.7 D, panels from left to right). For all three
setups, a prominent shift can be observed induced by the association of the complex with its nucleic
acid substrate. Taken together, these EMSA experiments point out that the METTL3/14 complex has
an aﬃnity towards polyanionic macromolecules and does not display any type of substrate speciﬁcity
when confronted with diﬀerent types of nucleic acids.
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2.3 Mapping of protein-interacting regions of METTL3, METTL14 and WTAP
Within published reports and the previous sections of this work, it has been demonstrated that the
METTL3/14 complex is suﬃcient to catalyze the methylation of adenines within a given RRACH motif
in vitro.168 Both proteins are also essential for maintaining the m6A-methylome of mRNA molecules
within the cell nucleus.168 Besides METTL3 and METTL14, a third protein has been identiﬁed that is
essential for the function of the methyltransferase complex within the cell by directly interacting with
METTL3. This interactor is WTAP and has so far been described as an auxiliary protein of the dimeric
complex.168, 170 This protein is crucial to transport METTL3/14 from the nucleoplasm into nuclear speck-
les. Interfering with the import into these sub-nuclear structures results in a reduction of global m6A-
methylation present on mRNA. The next experiments should further characterize the interaction of
WTAP with METTL3. The interacting regions between both proteins should be mapped using trunca-
tion constructs of both WTAP and METTL3. In addition to this, the dimerization domain of METTL3 and
METTL14 should bemapped in a similar fashion aswell, since no structural information of theMETTL3/14
complex has been published. The results obtained from these experiments should allow to gain a ﬁrst
insight into the architecture of the human N6-methylatransferase and its interaction with WTAP.
2.3.1 A short helix at the N-terminus of METTL3 is suﬃcient to interact with WTAP
As a ﬁrst approach tomapping the interaction betweenWTAP andMETTL3, a global structure prediction
of WTAP was made analogous to the one that was carried out for METTL3 and METTL14 (Fig. 2.8 A and
see section 2.1). Psipred predicts that the C-terminus of the protein is not structured at all, whereas the
N-terminal region consists of seven individual α-helices (Fig. 6.3 in the appendix). The primary sequence
of WTAP was additionally scanned with the algorithm COILS that calculates the likelihood of proteins
forming coiled-coil structures (Fig. 2.8 B).183 This bioinformatic approach was selected due to the high
abundance of helices in the N-terminus ofWTAP, some of which span over more than forty amino acids.
The algorithm scans the primary sequence of a given protein in deﬁned windows of 14 (in green), 21 (in
blue) or 28 (in red) amino acids. COILS scans proteins for heptad-sequences that are characteristic for
coiled-coils and assigns these regions a probability score between zero and one (Fig. 2.8 B). The higher
the score the better these regions fulﬁll the criteria of forming these tertiary protein structures. By using
this tool, three distinct regions could be detected that posses coiled-coil properties. The ﬁrst coiled-coil
of WTAP lies within its N-terminus and can only be detected within a sliding-window of 14 and 21 amino
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Figure 2.8 Prediction of a coiled-coil domain of WTAP and a potential interacting region within METTL3 A) Schematic repre-
sentation of the predicted domains of WTAP and METTL3 using Psipred. The coiled-coil prediction algorithm COILS indicates
that the N-terminal region of WTAP consists of a collection of three predicted coiled-coils. Within METTL3, two coiled-coil
predictions were found within the ﬁrst and second structured region of the protein. The ﬁrst structured region of METTL3 has
been termed the leader helix (LH) and was chosen as a candidate to test the interaction with WTAP. Predicted coiled-coils of
WTAP and METTL3 are indicated with an arrow head above each plot.
acids with an observed probability score of more than 0.8 (or 80%). The remaining two coiled regions
can be detected for all three search-intervals with similar scores as observed for the ﬁrst coil. Based on
this data, a hypothesis could be formulated that the N-terminus of WTAP contains a coiled-coil domain
and could be a possible interaction surface for METTL3.
As multimeric coiled-coils have been described to facilitate protein-protein binding, it is possible that
the METTL3-WTAP interaction could be mediated by this mechanism.184–186 Therefore, METTL3 was
scanned using the same tool to investigate if this protein as well contains any regions that fulﬁll the
requirements of forming a coiled-coil. In silico analysis reveals two probable coiled-coil regions (Fig. 2.8
B). Interestingly, one of the two regions has a score of over 90% within two of the applied scanning-
intervals. This predicted coiled-coil is located within the ﬁrst 34 amino acids of the N-terminus of
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METTL3, which has been termed the "leader helix", and was chosen as a ﬁrst candidate for further
biochemical investigations.
To test if this N-terminal segment of METTL3 possess the capability to bind to WTAP, a construct was
designed in which the leader helix was fused to the C-terminus of GFP (GFP-LH). The plasmid encoding
this fusion protein was coexpressed with a vector harboring a myc-tagged WTAP in HEK 293T cells.
With these cells, a myc-IP was performed and binding of the GFP-LH construct was assessed in a anti-
GFP immuno blot (Fig. 2.9 A). Interestingly, the short fragment from METTL3 fused to GFP is eﬃciently
copuriﬁed with WTAP during the IP (lane 2), whereas in the absence of the myc-tagged protein no
enrichment of the leader helix can be detected (lane 4). Within a control IP (lane 6), a band representing
GFP can be detected in the IP although the leader helix is not present. However, this GFP band is likely
to be the result of unspeciﬁc binding that is promoted by the high expression of the ﬂuorescent protein,
as seen in the input (lane 5; 3-4 fold higher as in lanes 1 and 3).
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Figure 2.9 The METTL3 leader-helix is essential for the METTL3-WTAP interaction A) A GFP-LH fusion protein was tested if
it can eﬀectively bind to myc-tagged WTAP, which was immuno-puriﬁed from HEK 293T cells expressing both constructs. B)
WTAP-binding was compared between wild typeMETTL3 and a construct missing the LH-region (ΔLH-METTL3). A myc-IP was
performed to enrich forWTAP and the possible copuriﬁcation of the twoMETTL3 constructs was examined in a Hemagglutinin
(HA) immuno-blot. FH, FLAG/HA-tag
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As a complementary experiment to test the observation made with the GFP fusion protein, the same IP
experiments were performed using a mutant of METTL3, in which the leader helix was missing (ΔLH-
METTL3; Fig. 2.9 B). When enriching for WTAP and performing a Hemagglutinin (HA) immuno-blot, the
mutant is not eﬃciently copuriﬁed in comparison to the wild type construct of METTL3 (lanes 6 and 2,
respectively). This indicates that the binding capability between METTL3 and WTAP is impaired when
the ﬁrst N-terminal helix from METTL3 is missing. Taken together, both experiments provide evidence
for a role of the leader helix facilitating the interaction between WTAP and the METTL3/14 complex.
2.3.2 Mapping of the METTL3-interacting region of WTAP
Next, the protein region of WTAP should be determined that binds to METTL3. For this, C-terminal
truncations of WTAP (CT) were designed by ﬁrst removing the predicted unstructured portion of WTAP
(C-terminus; see Fig.2.8 A) and then deleting step-wise Psipred-predicted α-helices (Fig. 2.10 A and see
appendix Fig. 6.3; constructs cloned by Christian Rittinger, University Regensburg). These constructs all
bear a myc-tag at their N-terminus and were cotransfected with FLAG/HA-taggedMETTL3 (FH-METTL3)
into HEK 293T cells. Lysates from these cells were then the starting material for FLAG-IPs (Fig. 2.10 B).
The constructs CT1 to CT3 copuriﬁed with FH-METTL3 to a similar extent as the wild type WTAP (lanes
8, 10, 12 and 6 respectively). On the other hand, the shortest of the tested constructs (CT4) failed to
copurify with METTL3 (lane 14).
In order to further test this observation, a second experiment was carried-out using the same WTAP
truncations. This time, however, the constructs were coexpressed in HEK 293T cells with the GFP-LH
fusion protein, which has been shown in the previous section to bind to full-length WTAP (Fig. 2.10 C).
In this experiment, a myc-IP was conducted to enrich for the individual WTAP constructs. An anti-GFP
immuno blot was then performed to investigate which of the CT-constructs can eﬃciently copurify the
METTL3 leader helix. Interestingly, the same constructs (CT1-3) that bind to the full-length METTL3 also
bind to the GFP fusion protein (lanes 8, 10 and 12). However, the interaction observed for the construct
CT3 is not as intense as for the other two WTAP versions. This experiment also could display that the
construct CT4, again, fails to associate with the presented METTL3 construct.
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Figure 2.10 METTL3-binding capability of WTAP resides within its ﬁrst 150 amino acids A) Schematic of the C-terminal trun-
cations of WTAP (CT) generated to map the METTL3-binding region of this protein. B) Truncations shown in A) or the full
length protein of WTAP were coexpressed with FLAG/HA-tagged METTL3 in HEK 293T cells. A FLAG-IP and afterwards an anti-
myc immuno blot was performed to detect constructs that can still bind to METTL3. C) HEK 293T cells expressing one of the
myc-tagged versions of WTAP and GFP-LH were subject to a myc-IP. Binding of the GFP fusion protein was then assessed in an
anti-GFP immuno blot.
These experiments suggest that the METTL3-interacting region of WTAP resides within the predicted
coiled-coil domain of the protein (aa 1-246). The truncation construct CT3, which can still bind to the
methyltransferase subunit, narrows the binding region down to the ﬁrst 151 amino acids of WTAP. In
order to more accurately map the METTL3-interaction domain, N-terminal truncations of WTAP (NT)
were constructed next and a complementary experiment was performed (Fig. 2.11 A). FLAG-IPs were
conducted in a similar fashion as carried-out for the C-terminal truncation constructs (Fig. 2.11 B). This
experiment revealed that the deletion of the ﬁrst 47 amino acids reduces the binding of the NT1 con-
struct to METTL3 (lane 8), but can still enrich it. The remaining two truncations showed no sign of
METTL3-binding, as no detectable signal is observed in the anti-myc immuno blot.
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Figure 2.11 Narrowing down METTL3-binding with N-terminal truncations of WTAP A) Schematic of the N-terminal trunca-
tions ofWTAP generated tomapMETTL3-binding. B) FLAG/HA-taggedMETTL3 was puriﬁed fromHEK 293T cells that addition-
ally expressed one of the diﬀerent myc-tagged WTAP constructs. Bound WTAP proteins within the IP sample were detected
in a anti-myc immuno blot.
Both truncation experiments point out that the region essential for METTL3-binding lies within the
amino acids 48 to 151. When comparing these ﬁndings with the coiled-coil prediction of WTAP, then it
can be hypothesized that the two ﬁrst predicted coils are involved in the binding of METTL3 (Fig. 2.12).
Evidence for this is given by the fact that both constructs showing no binding to METTL3 (indicated in
red) are missing one of the two predicted coil-regions, whereas the constructs showing reduced but
detectable association (indicated in green) still harbor both structured segments of WTAP.
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Figure 2.12 Summary of the WTAP truncation experimentsWTAP truncation constructs showing signiﬁcant METTL3-binding
(in green) and those with no observable binding (in red) were compared with the coiled-coil prediction of WTAP. Predicted
coiled-coils are indicated above the coil-plot diagram with arrow heads.
2.3.3 Investigating METTL3-METTL14 dimerization
METTL3 andMETTL14 have been reported to form a stable dimer.168 However, the exact interaction sur-
face or protein domain that promotes this dimerization had not been determined when these experi-
ments were planned. Since bothMETTL proteins share a common domain, namely theMT-A70 domain,
this regionwas the ﬁrst candidate to test its dimerization capability. For this, a similar approachwas cho-
sen as applied for the mapping of the WTAP-METTL3 interaction. Three untagged METTL14 truncation
constructs (METTL14-F1 to F3) were designed, in which the N- and C-terminal portion around the MT-
A70 domain were removed in diﬀerent combinations (Fig. 2.13 A). Each construct was then cloned into
an expression vector encoding for a GST-taggedΔLH-METTL3 fusion protein (constructs were designed
and cloned by Dr. Nora Treiber, University Regensburg).
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These vectors were utilized to generate baculovirus stocks that were used to infect Sf21 cells for re-
combinant expression of the METTL protein variants. Lysates from these cells were then subjected
to a GST-pulldown experiment that should enrich for theΔ-LH-METTL3 construct (Fig. 2.13 B). The re-
trieved eluates from this experiment were assessed in a coomassie gel to inspect which of the untagged
METTL14s could be eﬃciently copuriﬁed with METTL3. Interestingly, all untagged versions of METTL14
could be detected (lanes 2-4), even the smallest construct that solely contains theMT-A70 domain (lane
4). This experiment also indicates that the leader helix of METTL3 is not necessary for the interaction
between both METTL proteins (lane 1).
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Figure 2.13 METTL14 dimerizes with METTL3 via its MT-A70 domain A) Schematic of the constructs used to determine the
dimerization domain of METTL14. B) Sf21 cells were infected with baculoviruses that promote the co-overexpression of GST-
taggedΔLH-METTL3 and one of the diﬀerent untaggedMETTL14 constructs shown in A). The GST-taggedMETTL3 variant was
enriched during a GST-pulldown experiment. METTL14 proteins that could be eﬃciently copuriﬁed with this approach were
detected in a Coomassie gel.
This experiment indicates that the dimerization region of METTL14 resides within its MT-A70 domain.
From this data, it was hypothesized that METTL3 interacts with its MT-A70 domain in a similar fashion.
In order to validate the previous experiment and to gain evidence for the proposed working hypothesis,
a cross-linking and mass spectrometry experiment (CX-MS) was conducted in close collaboration with
the group of Franz Herzog (LMU, Munich). For this experiment, full-length METTL3 and METTL14 were
expressed and puriﬁed as described within the ﬁrst section of this work (see section 2.2.3). The native
protein complex was then treated with a chemical cross-linker and subsequently digested with a pro-
tease. The resulting cross-linked protein fragments were afterwards analyzed via mass spectrometry.
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The detected intermolecular (in blue) and intramolecular (in red) cross-links were then visualized with
the online tool xVis Crosslink Analysis Webserver (Fig. 2.14; experiment preformed by Götz Hagemann,
LMU).
METTL3METTL14
MT-A70MT-A70
Figure 2.14 Investigating METTL3-METTL14 protein interaction via a chemical cross-linking combined with mass spectrome-
tryRecombinantMETTL3/14 complexwas puriﬁed as described in a previous section of thiswork. The native complexwas then
chemically cross-linked and subsequently fragmented using a protease. The resulting cross-linked peptides were analyzed via
mass spectrometry. Intermolecular and intramolecular cross-links are indicated in blue and red respectively.
Since the GST-pulldown experiment provided evidence for the interaction of the MT-A70 domain of
METTL14 withMETTL3, cross-links within this region were closely examined. Opposite to the ﬁndings of
the pulldown experiment, no cross-links were found that would conﬁrm the hypothesized interaction of
the MT-A70 domains of both METTL proteins. The cross-linking events found within the MT-A70 region
of METTL14 were either associated with the second structured domain of METTL3 or its C-terminus.
When examining the MT-A70 domain of METTL3, then only a single intermolecular crosslink with the
N-terminus of METTL14 can be detected.
Crosslinks detected in this approach are dependent on the chemical crosslinker utilized in the prepara-
tion of the samples as well as the distance of the functional groups that can form covalent bonds with
the agent. It is therefore possible that the interaction observed in the GST-pulldown is not detected in
this experiment, because the appropriate reagent was not used or the cross-linkable amino acids within
both MT-A70 domains were to far apart from each other. In conclusion, the results obtained from this
experiment do not provide a clear-cut view on the exact dimerization region of METTL3 and does not
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support the proposed interaction of METTL14’s MT-A70 domain with METTL3.
2.4 Investigating nuclear import of the METTL3/14 complex and WTAP
Both the METTL3/14 complex as well as the auxiliary protein WTAP reside in the nucleus.168, 170 In the
literature it has beendemonstrated thatWTAP is not required to import theMETTL3/14 complex into the
nucleus, as the complex resides in the nucleoplasmn ifWTAP is depleted from the cell.170 However, it has
not been determined on how these components are imported into the nucleus. The next experiments
should investigate if all three known interacting proteins possess a functional nuclear localization signal
(NLS). Additionally, experiments were conducted to explore if the METTL3/14 complex is assembled in
the cytoplasm and imported as a whole or if the individual subunits are ﬁrst imported into the nucleus
before assembly.
2.4.1 Both WTAP and METTL3 possess a predicted and functional NLS
The primary sequences of WTAP, METTL3 andMETTL14 were scanned using the Eukaryotic Linear Motif
resource tool to identify sequences that resemble canonical NLSs (see 5.2.6.4).180, 181 For all three pro-
teins, high conﬁdent predictions could be determined (Fig.2.15 A-C). A characteristic feature of NLSs are
positively charged amino acids that are critical for the interaction with factors (such as importins) that
facilitate the import of cargo proteins into the nucleus.187–189 Point mutations (Fig.2.15 A-C; indicated
in red; designed and cloned by Franziska Weichmann, University Regensburg) were introduced into the
predicted NLS of all three proteins (NLS-mut). Thesemutant constructs were then transfected into HeLa
cells. The localization of the resulting proteins was then assessed during immunoﬂuorescence experi-
ments (all IF experiments conducted by Franziska Weichmann, University Regensburg) and compared
with the corresponding wild type construct. As expected, the wild type constructs of WTAP, METTL3
and METTL14 show a clear nuclear signal. Interestingly, the nuclear import of the two NLS mutants
of WTAP and METTL3 seems to be impaired after introducing the indicated mutations. However, the
METTL14 mutant still localized within the nucleus. This indicates that this protein either does not pos-
sess a canonical NLS or is imported via a diﬀerent mechanism. .
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Figure 2.15 WTAP and METTL3 posses functional nuclear localization signals A) The potential NLS of WTAP was predicted in
silico and positively charged residues were exchanged for glycine (indicated in red). The import of wild type and NLS mutante
WTAP was assessed in an immune ﬂuorescence experiment conducted in HeLa cells. The approach described for WTAP was
also applied for METTL3 (M3; B) and METTL14 (M14; C). Numbers indicate the amino acid position of the predicted NLS for
each protein. FH, FLAG/HA-tag; WT, wild type
.
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2.4.2 The interaction with METTL3 is essential for the nuclear import of METTL14
After this mutational experiment, a hypothesis was formulated. This proposes that the translocation of
METTL14 across the nuclear envelope could rely on the interaction withMETTL3. This in return requires
the cytoplasmic formation of the minimal methyltransferase complex before it is imported into the
nucleus. In this model, the nuclear transport of the protein complex would only need a single functional
NLS and not one for each individual subunit. To test this working-hypothesis, the myc-tagged "NLS
mutant" of METTL14 (M14-NLS-mut) was coexpressed in HeLa cells with either the wild type construct
or NLS mutant of METTL3 (M3 and M3-NLS-mut respectively, both FLAG/HA-tagged). The localization
of the METTL proteins was then investigated via an immunoﬂuorescence experiment (Fig. 2.16 A).
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Figure 2.16 The import ofMETTL14 into the nucleus relays on an intactNLS ofMETTL3A)Wild type orNLSmutantMETTL3 (M3
andM3-NLS-mut respectively) was cotransfected in HeLa cells with the predicted NLSmutant ofMETTL14 (M14-NLS-mut). The
localization of theMETTL proteins was then assessed via immunoﬂuorescence. B) Both wild type and NLS mutants of METTL3
(FLAG/HA tagged) and METTL14 (myc-tagged) were transfected in diﬀerent combinations into HEK 293T cells. FLAG-IPs were
performed to examine the binding capability of the diﬀerent METTL3 and METTL14 variants.
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Transfection of the predicted NLS mutant of METTL14 together with wild type METTL3 show a nuclear
abundance of both proteins within HeLa cells (upper panels). Interestingly, when the NLS mutant of
METTL3 is coexpressed, then the same METTL14 construct is retained in the cytoplasm (lower panels).
In order to test if this relocalization of METTL14 relies on a direct interaction with the NLS mutant of
METTL3, co-immunoprecipitation experiments were conducted (Fig. 2.16 B). Within these experiments,
diﬀerent combinations of wild type and NLS-mutant constructs were tested. Wild type METTL3 can
still eﬃciently copurify the predicted NLS mutant METTL14 in anti-FLAG-IPs (lane 14), indicating that the
introduced mutation has no eﬀect on the dimerization of both METTL proteins. Interestingly, a stable
interaction of METTL14 is also detectable when precipitating the mutant variant of METTL3 (lane 10),
suggesting that the cytoplasm localization of METTL14 could be the result of the binding to the METTL3
NLS-mutant.
The results from these experiments provide evidence that the nuclear import of METTL3 and METTL14
relies on the identiﬁed NLS present in METTL3. This observation also favors the hypothesis that the
dimeric methyltransferase complex is most likely formed in the cytoplasm and translocated as a whole
across the nuclear envelope. The data gathered within this work provides a ﬁrst insight into the import
of core components of the m6Amethyltransferase as well as the interaction regions between the three
known interactors. Finally, biochemical analysis of the METTL3/14 complex clearly show that METTL14
is not necessarily the catalytic subunit within the dimer, thus changing the currently established model
on m6A-formation.
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3.1 A revised view on METTL3/14 catalysis
The current view on the formation of m6A was mainly provided by a report published by Liu and col-
leagues.168 The group identiﬁed METTL14 as an additional component of the N6-adensosine methyl-
transferase complex and analyzed the catalytic activity of the two METTL proteins separately. During
this experiment it was observed that METTL14 alone possesses a higher methyltransferase activity than
METTL3. This led to the assumption that METTL14 is the catalytic subunit of the METTL3/14 complex.
However, since this publication, another report has indicated some controversy. Experiments conducted
by another group suggest that METTL3 and METTL14 by themselves are not stable. This is not only true
in vitro, but has been demonstrated as well in vivo.169 These ﬁndings, therefore, challenged the conclu-
sion made during the initial report of the METTL3/14 complex concerning the activity of each subunit
outside the context of the assembled dimer. During this thesis this controversy should be further bio-
chemically investigated.
The results obtained from the SAM cross-linking (see Fig. 2.3) experiment and the mutational analysis
using the recombinant APPA mutants (see Fig. 2.6) suggest that the activity of the binary complex is
solely dictated by METTL3 . Diﬀerent publications provide further evidence for this hypothesis. Early
fractionation experiments conducted to enrich for the m6A-methyltrasferase from nuclear extracts, led
to the initial identiﬁcation of METTL3.167 In a SAM-binding experiment similar to the one conducted
here, the group could only identifyMT-A70 (METTL3) as the SAM-binding subunit of the complex.167 The
authors further demonstrated that their isolated MT-A70 containing complex is active and can methy-
late substrates within a RRACH motif. These characteristics point-out that the authors examined the
samemethyltransferase complex as the one investigated in this thesis. To that time, however, it was not
known that METTL14 is a crucial component of the methyltransferase. Nevertheless, it can be assumed
that METTL14 was also present in the complex studied by Bokar and colleagues, since their complex
displays the same biochemical properties as observed for the puriﬁed METTL3/14 dimer.169
Another report that underlines the proposed importance of METTL3 in the formation of m6A was pre-
sented by Fustin and colleagues.190 This group investigated the cellular circadian clock and the impact
METTL3 has on it. A METTL3 construct was designed in which the DPPW-motif was mutated. Upon
the expression of this construct, the length of the circadian periods within the cell were extended in
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comparison to the wild type control. However, the group did not investigate if these mutations have
an eﬀect on global m6A-levels present on mRNA and was only assumed. Nevertheless, this study could
show that an intact DPPW-motif within METTL3 is crucial for the cell and it has been demonstrated that
this motif is key for the catalytic function of other methyltransferases.178, 182 Therefore these studies
further favor a catalytic involvement of METTL3 within the dimeric methyltransferase complex.
The most convincing evidence conﬁrming the ﬁndings of this work that METTL3 is truly the active sub-
unit within the METTL3/14 dimer, has been provide by two independent groups. During the prepara-
tion of this thesis, two crystal structures of the methyltransferase domains (MTDs) from METTL3 and
METTL14 have been published.191, 192 Additional structures were obtained in which the protein com-
plex was co-crystallized with the methyldonor SAM (Fig. 3.1 A-C). Both structures reveal that SAM is
only associated within a binding pocket of METTL3, and therefore conﬁrming the ﬁnding of the SAM
cross-linking experiment. When examining the SAM-bound METTL3 structure, it can be seen that the
methyldonor is not only in close proximity of the DPPW-motif, but is also coordinated by the aspartate
of the tetrad ( Fig. 3.1 B and C).
A
B C
Figure 3.1 Crystal structure of the MT-A70 domain of METTL3 and METTL14 A) Overall structure of the MT-A70 domains of
METTL3 (purple) and METTL14 (green). B) Close-up of the SAM-binding pocket within METTL3. Indicated in orange are the
residues that form the DPPW-motif, which are essential for METTL3 activity. C) Shown are the amino acids involved in the
coordination of SAM within the binding pocket of METTL3. Figure adapted fromWang et al.192
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These structures oﬀer direct evidence and an explanation for the observed loss of activity in theMETTL3
APPA mutant during the in vitro methylation assays. Upon mutation of D395, SAM-binding might be
greatly impaired or even obliterated and would result in the loss of methyltransferase activity. In-
deed, Wang et al.conducted isothermal titration calorimetry experiments that compared the wild type
METTL3/14 complexwith amutant variant ofMETTL3 (D395A) and could demonstrate that no signiﬁcant
SAM-bindingwas present in themutant variant of the binary complex.192 BesidesMETTL3,METTL14was
also in the scope of the mutational analysis of this thesis. The experimental results suggest that this
subunit is not directly involved in the formation of m6A , since mutation of the EPPL-motif showed that
methylation activity was still present. The observed reduction in activity of the METTL14 APPA mutant
was likely the result of the smaller quantities of the complex used during the assay. Similar to the exper-
iment conducted with the APPA mutants, the group that published the second structure also examined
METTL14 by introducing a single point mutation, the glutamate of the EPPL-tetrad was exchanged for
an alanine (E192A).191 In agreement with the ﬁndings of this thesis, no signiﬁcant reduction could be
observed when the predicted catalytic sequence of METTL14 is altered.
Both published crystal structures as well as the results gathered from the SAM cross-linking experiment
and the mutational study provide evidence that METTL3 alone is essential for catalytic activity of the
complex and that the EPPL-motif fromMETTL14 is not directly involved mechanistically. This, therefore,
revises the view in the ﬁeld that METTL14 is the catalytic subunit of the complex. Nevertheless, impor-
tant roles for METTL14 have been proposed by the two structure papers concerning complex stability
and substrate recognition, which are further discussed in the following sections.191, 192
3.2 Dimerization of METTL3 and METTL14
The GST-pulldown experiment suggests a role of the MT-A70 domain from METTL14 to directly be in-
volved in the dimerization with METTL3. However, the intended conﬁrmatory cross-link MS analysis
provided controversial results. When comparing both experimental approaches, then the results from
the batch puriﬁcation of the individualMETTL14 truncations providemore convincing evidence than the
MS analysis. This is due to the fact that all untagged METTL14 variants were copuriﬁed with GST-ΔLH-
METTL3. Since it is unlikely that all three diﬀerent METTL14 constructs were unspeciﬁcally copuriﬁed,
the obtained results imply that the dimerization region of METTL14 resides within the structured MT-
A70 domain.
By emphasizing the GST-pulldown results, how should the results of the CX-MS experiment then be in-
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terpreted? In order to detect protein-protein interactions within both the GST-pulldown as well as the
CX-MS method, a native, correctly folded and assembled protein complex is needed. While the GST-
pulldown experiment generates simple results (binding vs. no-binding) the CX-MS can provide more
detailed information of protein regions that are in close-proximity to each other.193 However, the de-
tection of the interactions between protein regions rely on several elements: the chemical agent used
during the experiment, the distance and presence of cross-linkable functional groups.194
The CX-MS experiment performed in this work used bis-sulfosuccinimidyl suberate (BS3) as a chemical
cross-linker to generate the detected cross-linkedpeptides. This reagent is used to cross-link the primary
amine of lysines and the N-terminus.194 BS3 also possesses a linker that spans eight carbon atoms.
Since the CX-MS experiment of the METTL3/14 complex only utilized this single cross-linking agent, it
is possible that the interaction between the MT-A70 domains of both METTL proteins could not be
detected using this approach. In order to obtain a more accurate overview of the complex, diﬀerent
cross-linkers should have been tested. This might have identiﬁed high conﬁdent cross-links that would
agree with the results of the GST-pulldown experiment.
As mentioned in the last section, two crystal structures have been published that provide a detailed
view on the architecture of the MT-A70 domains of both METTL proteins (referred as MTD in both
publications).191, 192 Close examination of both METTL3/14 structures show that both proteins dimerize
via their MT-A70 domains (Fig. 3.2 A and B). Both domains establish an extensive network of hydro-
gen bonds between each other, resulting in a stable complex formation. A majority of the mapped
residues involved in the protein-protein interaction of METTL14 with METTL3 are also present in the
smallest METTL14 fragment (M14-F3) analyzed during the GST-pulldown experiment. The amino acids
R135, D136 and Y146 of METTL14 were, however, missing in this METTL14 truncation construct and are
shown in the crystal to also interact with METTL3 (Fig. 3.2 B (orange framed panel)).192 Since a eﬃcient
copuriﬁcation of METTL14 was observed, it can be assumed that these residues are not essential for the
overall complex assembly of both METTL proteins, but might further stabilize the complex.
Taken together, the obtained CX-MS results could not determine the dimerization domain of METTL3
and METTL14. However, the GST-pulldown experiments demonstrated that the MT-A70 domain of
METTL14 was likely to be involved in the complex formation and has been conﬁrmed through the re-
cently published structural studies. These structural reports additionally veriﬁed the assumption that
METTL3, as well, promotes the dimerization with METTL14 via its MT-A70 domain.
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A
B
Figure 3.2 Detailed view of the METTL3-METTL14 dimerization via their MT-A70 domains A) The dimerization interface of
METTL3 (colored wheat) and METTL14 (colored silver) are composed of the regions termed interface 1 and interface 2. Inter-
face 1 is highlighted by a orange and green box, whereas interface 2 is framed by a cyan rectangle. B) Detailed view of the
interface regions 1 and 2 showing the amino acids involved in the dimerization of both METTL proteins. The color of each
frame corresponds to the highlighted region in A). Figure adapted from the extended data section of Wang et al.192
3.3 Substrate-binding of the METTL3/14 complex
Methylation of adenine within a RRACH motif requires a direct interaction between the RNA substrate
and the METTL3/14 complex. Therefore, it has been proposed that the methyltransferase might also
contain a protein domain(s) that introduces speciﬁcity. Substrate speciﬁcity has been observed in vivo,
since not all RRACH motifs that are dispersed throughout mRNA become methylated.40,41 Another
topology aspect that underlines the need for speciﬁcity is demonstrated by the enrichment of m6A
within the 3’ end of mRNAs.40,41
EMSAs of full length METTL3 and METTL14 could demonstrate that the complex is capable of binding
an RNA substrate that has also been utilized during the in vitro methylation assays. However, closer
examination of the observed shifts has shown that the protein complex seems to bind to polyanions
in an unspeciﬁc fashion. This conclusion has been drawn as the binding of the methylatable RNA sub-
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strate can be eﬀectively abolished through the titration of yeast tRNA. In addition, diﬀerent nucleic acid
species (RNA, DNA or hybrid) containing an RRACHmotif could all interact with theMETTL protein com-
plex, since a detectable shift within the EMSAs was observed. A third aspect that further indicates that
the observed RNA-binding is unspeciﬁc is the fact that heparin can also interfere with the binding of the
substrate RNA.
Experiments conducted by Wang et al.support the observations made during this work, as the authors
have carried-out EMSAs using similar conditions.192 However, the authors did not evaluate the speci-
ﬁcity of the RNA binding by using diﬀerent substrates, polyanion additives or varying the concentration
of yeast tRNA. Within the structure of the same publication, a positive patch could be identiﬁed that
is likely to be responsible for the binding to polyanions, since their observed RNA substrate-binding is
greatly impaired upon the mutation of arginine and lysine residues residing within this patch. Careful
examination of the crystal structure also revealed that theMETTL3/14 complex seems to lack a canonical
target recognition domain (TRD). TRDs are protein domains essential for introducing target speciﬁcity
of nucleic acid modifying proteins.195, 196 The authors of the ﬁrst published structure of METTL3/14 pro-
pose thatMETTL14 could contain protein regions thatmight compensate the lack of a traditional TRD.192
When testing this hypothesis with the EMSA data provided by this work, then it can be argued that
target speciﬁcity of the protein complex might be achieved through another mechanism. The fact that
methylation occurs within a degenerated RRACH motif supports the idea that the METTL3/14 complex
might only posses a minimal speciﬁcity towards distinct RNA sequences and that the non-stochastic
distribution ofm6A is facilitated by another factor or factors. A recent publication by Patil et al. provides
experimental evidence that proteins other thanMETTL3 orMETTL14 might provide target speciﬁcity for
the m6A-methylation machinery.197
In this report, two RNA-binding proteins were identiﬁed, namely RBM15 and RBM15B, that interact
with the METTL3/14 complex via WTAP. In addition to the physical interaction of both RBM proteins,
binding sites of RBM15 and RBM15B were found in close proximity of m6A-sites within various mRNAs.
Depletion of either RBM protein or both have a direct impact on cellular m6A-levels, further supporting
the idea that these proteins introduce target speciﬁcity. Both RBM15 and RBM15B belong to the split
end (SPEN) protein family. All members of this family posses a similar protein architecture harboring
three RNA recognition motifs in their N-terminus and a SPEN-Paralog-Ortholog-Conserved domain in
the C-terminus.198 Interestingly, in Drosophila a protein termed Nito has been identiﬁed to interact
with the ﬂy homologs ofWTAP andMETTL3 (Fl(2)d and Ime4, respectively).199 Like RBM15 and RBM15B,
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Nito as well belongs to the SPEN family and depletion of the protein has also a direct consequence on
m6A-levels. Therefore, it can be assumed that the association of RNA-binding proteins with the m6A-
methyltransferase and guiding the complex to speciﬁc RNA targets could be a common theme that is
conserved between species.
These ﬁndings allow to hypothesize that the methylation of speciﬁc RRACH motifs is dictated by RNA
binding proteins that interact with the METTL3/14 complex and function as modular TRDs. These pro-
teinswould tether themethyltransferase to certain regionswithin target RNAs. The anchoredMETTL3/14
complex can then scan the surrounding RNA region for RRACH motifs and modify these once the sub-
strate is properly oriented within the dimeric methyltransferase. This model could elegantly explain
the lack of a TRD within the methyltransferase complex and why METTL3 and METTL14 do not have to
display a high degree of substrate speciﬁcity. Further studies will have to concentrate on the identiﬁ-
cation of further RNA binding proteins that interact with METTL3 and METTL14, or their homologs, in
order to further support the model proposed here, since not all methylation sites are inﬂuenced by the
RNA-binding proteins so far identiﬁed.
3.4 WTAP-METTL3 interaction
METTL3-WTAP interaction has been reported to be essential for the import of the methyltransferase
complex from the nucleoplasm into nuclear speckles.170 However, besides the localization of the com-
plex into these sub-nuclear structures, it is not exactly known what other molecular roles WTAP fulﬁlls.
In this work, investigating the interacting region between WTAP an METTL3 was ﬁrst carried out using
an in silico approach. Examination of the protein sequence of both proteins revealed that predicted
coiled-coils could be the underlining protein structures involved in their interaction. Protein-protein
interactions promoted by multiple coiled-coils forming homo- or heteromeric complexes have been re-
ported.184–186 Therefore, this was a valid working hypothesis that was further investigated.
Experiments were performed using N- and C-terminal truncations of WTAP and diﬀerent variants of
METTL3 to investigate this predicted interaction mechanism. These experiments provided evidence
that structures within the amino acids 48 to 151 of WTAP are essential for the direct interaction with
the methyltransferase subunit. The work conducted by Ping and colleagues could show that indeed
the WTAP region involved for the protein-protein interaction with METTL3 resides within the ﬁrst 200
amino acids of its N-terminus.170 However, no further mapping eﬀorts were made to narrow this region
down. Ultimately, structural information provided by cyro-electron microscopy or crystallization of a
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WTAP/METTL3/METTL14 complex could provide further evidence for the working model derived from
this work. However, both structural biology approaches rely on a robust heterologous expression of all
components of the WTAP-m6A-methyltransferase complex. Full length WTAP has been shown to easily
form large protein aggregates when expressed in E. coli (Master Thesis David Wunderlich conducted
within the Biochemistry I department) and insect cells.168 Therefore, it may be beneﬁcial to test a spec-
trum of soluble truncations of WTAP and try to co-crystallize these constructs with the METTL3 leader
helix.
An alternative approach to validate the coiled-coil promoted interaction could be the construction and
expression of reﬁned WTAP mutants and repeating the performed Co-IP experiments. Coiled-coils are
generally composed of so-called heptad repeats and the amino acids within these repeats are denoted
with the letters a, b, c, d, e, and f (Fig. 3.3 A).200 In many coiled-coils, hydrophobic amino acids are
found within the positions a and d of the repeats. Amino acids at these positions are known to form
a hydrophobic interface between coil-forming α-helices and enable their association with one another
(Fig. 3.3 B).201, 202 Using this information, one strategy to provide further evidence on the coiled-coil-
mediated interaction betweenWTAP andMETTL3 would be to mutate amino acids within the positions
a and d of the heptad repeats found in both proteins. An exchange of these hydrophobic amino acids
for more hydrophilic ones could result in the loss of the observed interaction. Publications have shown
that an exchange of amino acids at these positions can indeed promote the destabilization of coiled-
coils.184, 203 WTAP or METTL3 leader helix constructs bearing these mutations could be tested within
the system used in this work and add further information on the exact interaction mechanism of both
proteins.
A B
Figure 3.3 General structure of a coiled-coil A) Shown in a wheel diagram are two α-helices that form a coiled-coil. The amino
acids of the heptad repeat of each helix are denoted from N- to C-terminus as a-f or a’-f’. Amino acids within the a/a’ and d/d’
position interact with its corresponding interaction partner via hydrophobic forces, whereas residues in position g/g’ and e/e’
interact through hydrophilic forces with each other. B) Amino acids within the a/a’ and d/d’ position of several heptad repeats
form a hydrophobic surface that is essential for the formation of a coiled coil. Figure adapted from Mason and Arndt200
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3.5 Cellular localization of the core methylation machinery components
All factors of the core methyltransferase machinery, namely WTAP, METTL3 and METTL14, are localized
within nuclear speckles.168, 170 For the proper import into the nucleus, many nuclear proteins rely on
an NLS embedded within their primary sequence.187 Results from the IF experiments conducted within
this work suggest that both WTAP and METTL3 posses a functional NLS that is required for their proper
localization. Both signals can be categorized as classical monopartite NLS. These NLS are characterized
to posses a signal stretch of basic amino acids that resembles the monopartite NLS of the simian virus
40 large T-antigen, which is considered a strong NLS due to its extensive characterization.204–206 Using
the NLS-scanning algorithm of the Eukaryotic Linear Motif resource tool, a classical monopartite NLS
was also predicted for METTL14. Mutational analysis could, however, not provide evidence that this
proposed NLS is actually functional. As a consequence it can be argued that METTL14 is imported into
the nucleus via a diﬀerent mechanism or utilizes an "exotic" NLS. This model would suggest that either
the METTL proteins are imported separately or that the METTL3/14 complex as a whole is transported
into the nucleus, which can be mediated by two diﬀerent NLS. This, in return, would also suggest that
the assembly of the METTL3/14 complex could occur both in the nucleus and the cytoplasm.
Besides this hypothesis another one was suggested that takes into account that each METTL protein
by themselves are quite unstable.169 With this stability issue, it seems more favorable for both pro-
teins to dimerize upon completion of translation followed by the import of the whole METTL3/14 com-
plex into the nucleus. Within this working model, a single NLS would be suﬃcient to localize the m6A-
methyltransferase into the nucleoplasm, since the transport into nuclear speckles relies on the inter-
action with WTAP.170 Evidence for this model could be provided through the IF experiments. However,
further experiments should be preformed to further back-up the formulated hypothesis. For instance, a
complementary experiment could be to conduct the same experiments in a METTL3 knock-out cell line
(generated using the CRISPR/Cas9 technology207). Within this deﬁned genetic background, it should be
possible to convincingly show the import of METTL14 via METTL3 during a rescue experiment. METTL14
should reside in the cytoplasm in the absence of ectopic METTL3. The proper localization of METTL14
should be displayed by the knock-out cell line after METTL3 has been reintroduced into the cells.
Within the ﬁeld, it has been accepted that all core methyltransferase components are imported into
the nucleus and carry-out their function within this compartment of the cell. A recent report from
Lin et al. demonstrated that METTL3 seems to also fulﬁll a certain biological function within the cyto-
plasm.208 The authors provide evidence for the existence of two distinct METTL3 pools. The ﬁrst pool
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associates with METTL14 and localizes to the nucleus to carry out the methylation of mRNA transcripts.
The proposed secondMETTL3 population resideswithin the cytoplasm and stimulates translation, with-
out METTL14 being present. Up-regulation of protein synthesis promoted by METTL3 was shown to be
independent of the catalytic activity of the m6A-methylatransferase subunit. When comparing these
ﬁndings with the body of literature that has been published during the last ﬁve years and also taking
the data generated during this work, severalmajor questions arise that seem to contradict the proposed
role of METTL3 in the cytoplasm.
Onematter concerns again the stability of amonomericMETTL3. It has been convincingly demonstrated
that this protein mostly relies onMETTL14 binding to prevent its degradation when present alone in the
cell.169 This fact implies that METTL3 has to be stabilized through a protein other than METTL14 or that
it is stabilized through a completely diﬀerent mechanism. A proposed alternative stabilizingmechanism
could be through the auto-assembly of METTL3. However, there is to date no experimental evidence
that METTL3 can indeed form homo-dimers or a higher complex structures by itself that might have a
similar stabilizing eﬀect as seen for the interaction with METTL14.
Another question concerning the cytoplasmic role of METTL3 is how does this protein interact with cy-
toplasmic target mRNAs? Lin et al.demonstrate that the observed enhancement of translation does not
depend on theMT-A70 domain ofMETTL3 but on the ﬁrst 200 amino acids of the protein. The two pub-
lished crystal structures clearly display the need of both MT-A70 domains of METTL3 and METTL14 for
the binding of RNAs or negatively charged molecules in the nucleus. This would lead to the assumption
that METTL3 could posses an additional RNA binding region distinct from its catalytic domain or that
another protein that interacts withMETTL3 facilitates the binding to the targetmRNAs in the cytoplasm.
This issue needs to be addressed to provide further evidence for the role of METTL3 in diﬀerent com-
partments of the cell. Finally, a last aspect that deserves further investigation is howMETTL3 can evade
its import into the nucleus or how the protein can shuttle between the nucleus and the cytoplasm. The
IF experiments conducted in this thesis clearly demonstrate that METTL3 posses a functional classical
NLS. This leads to the hypothesis that the import signal of METTL3 has to be somehow repressed in
order to stay in the cytoplasm or that the protein possesses an additional nuclear export signal (NES)
that allows the shuttling of the protein between both cellular compartments.209–212
The suppression of an NLS can occur through diﬀerent mechanisms. One possibility would be that the
NLS ismasked by another protein and thus prevents the binding of importins.188, 189 An alternativemode
of action to prevent the import of proteins into the nucleus is through the modiﬁcation (e.g. phospho-
rylation) of sites adjacent to the NLS.213, 214 These possibilities need to be investigated biochemically
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and would provide a plausible answer on how METTL3 can be localized in the cytoplasm even with a
functional NLS.
This discussion demonstrates that the import of the core methyltransferase components is barley un-
derstood. It is also not clear if the association of WTAP with the METTL3/14 complex occurs ﬁrst in the
nucleus or can already take place in the cytoplasm. The presence of a functional NLS in both METTL3
and WTAP could argue for the assembly of the trimeric complex (WTAP/METTL3/METTL14) in the nu-
cleus, since the import of METTL3 and METTL14 most likely relies on a single NLS in METTL3. Another
interesting matter would be to investigate which importin or importins facilitate the transport of the
core methyltransferase components across the nuclear envelope.215, 216 Dissecting this is, however, far
from trivial, since the nuclear transport of some cargo proteins can be facilitated by more than one
importin.217, 218 Dissection of this cell biological aspect could also reveal a potential mechanism on how
m6A-levels can be regulated through alternative sub-cellular localization or how components of the
methyltransferase (e.g. METTL3) can fulﬁll other physiological roles within the cell.
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The ﬁeld of post-transcriptional RNAmodiﬁcations has quickly expanded over the last 5 years. This area
of research has provided some insight on a new regulatory layer present on RNA that has a signiﬁcant
impact on gene expression and RNA function (see section 1). Within this ﬁeld, m6A has been the most
intensively studied mRNA modiﬁcation. Even though the core methyltransferase has been identiﬁed
and several m6A-based mechanisms have been described, many biological aspects of this nucleic acid
modiﬁcation still remain elusive.
This work could provide evidence that the catalytic activity of theMETTL3/14 complex is solelyMETTL3-
dependent and does not rely on METTL14, which was previously reported.168 A direct consequence of
this observation is to ask the question: what is then the exact role of METTL14 in the complex? So
far it seems that METTL14 only functions as a stabilizing factor of the dimeric methyltransferase. How-
ever, potential functions for METTL14, such as promoting the interaction with additional proteins asso-
ciated with the binary complex, cannot be ruled out. Protein domains that lie outside of the MT-A70
domain of METTL14 could harbor the protein-protein interactions sites needed for this task. A ques-
tion that arises from an evolutionary standpoint is why a second non-functional but highly conserved
methyltransferase-like protein is incorporated in theMETTL3/14 complex? Further investigations focus-
ing on the catalysis of the methyltransferase complex might provide an explanation.
Another aspect of them6A-methyltransferase that needs to be further studied is the composition of the
fully assembled complex in vivo. The initial characterization from Bokar and colleagues described the
humanm6A-methyltransferase as a large protein complex with a predicted molecular weight of greater
than 1MDa.166, 167, 219 This observation suggests that a complex exists that possesses more factors than
the ones to date identiﬁed and validated, namely WTAP, METTL3 and METTL14. The identiﬁcation of
these novel interactions partners and investigating their role within the complex is currently one of the
most investigated areas within the ﬁeld. The RNA-binding proteins RBM15 and RBM15B are the newest
factors to be considered an integral part of them6A-machinery.197 Thediscovery of these proteinsmight
provide a molecular explanation on how METTL3 only methylates a certain pool of RRACH-associated
adenosines located in the 3’-UTR of mRNAs. However, not all m6A-methylation sites that have been
mapped so far possess a binding motif for one or both RBM proteins.197 This leads to the assumption
that additional RNA-binding proteins might associate with the methyltransferase in order to target the
remaining methylation sites.
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Identiﬁcation and characterization of these additional components of the m6A-methyltransferase com-
plex could in return also help draw a clearer picture on when exactly this post-transcriptional modi-
ﬁcation is established. So far, hypotheses have been formulated that link m6A-formation with splic-
ing.41, 168, 169 However, no direct biochemical evidence has been provided to conﬁrm this assumption.
These last sections clearly highlight that even though several aspects of methyltransferase complex are
now becoming clearer, many other facets still remain elusive. This is not only true for the METTL3/14
complex, but also for other proteins associated with m6A , such as the "readers" and "erasers". One
challenge for the future will be to investigate the potential cross-talk between the "writer", "readers"
and "erasers" and how this interaction manifests into a biological response. The ﬁndings from these
studies will eventually help to understand this additional layer of gene regulation and how the epitran-
scriptome contributes to development and disease within diﬀerent organisms.
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5.1 Material
5.1.1 Chemicals and Consumables
All chemicals (analytical grade) were purchased from AppliChem GmbH (Darmstadt, Germany), Sigma-
Aldrich (St. Louis, USA), Merck (Darmstadt, Germany), Roth (Karlsruhe, Germany) and Thermo Fisher
Scientiﬁc (Waltham, USA) unless otherwise stated.
Commercially available kits for the isolation of nucleic acids from diﬀerent sources were purchased
from Macherey-Nagel (Duüren, Germany), GE Healthcare (Little Chalfont, UK) or Thermo Fisher Scien-
tiﬁc (Waltham, USA). Cell culture media and supplements were obtained from Sigma-Aldrich (St. Louis,
USA). Radioisotopes were purchased from Hartmann Analytic GmbH (Braunschweig, Germany). En-
zymes, nucleotides and RNA / DNA / protein standards were purchased from Thermo Fisher Scientiﬁc
(Waltham, USA). DNA and RNA Oligonucleotides used in this work were purchased and synthesized by
Metabion GmbH (Planegg, Germany) or Biomers (Ulm, Germany).
5.1.2 Oligonucleotides
Listed in the following tables (Tab.5.1 - 5.3) are the DNA, RNA and hybrid (RNA+DNA) oligonucleotides
that were used in this thesis.
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Table 5.1 DNA oligonucleotides used for cloning
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Table 5.2 DNA oligonucleotides used as templates for T7 in vitro transcription reactions
Table 5.3 Nucleic acid substrates for EMSAs
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5.1.3 Vectors
The Vectors that are listed in the following table (Tab.5.4) represent: (1) plasmid backbones for the
construction of mammalian expression plasmids, used in combination with the DNA oligonucleotides
listed in Tab.5.1, (2) mammalian expression plasmids encoding for control proteins (e.g. VP5-GFP) or (3)
plasmids designed and cloned by Dr. Nora Treiber (Regensburg University, Biochemistry I) that were
used for the recombinant expression of proteins in Sf21 cells.
Table 5.4 Vectors used for cloning and already cloned constructs used in this work
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5.1.4 Antibodies
In the following table (Tab.5.5) are the antibodies utilized for western blots (WB), immunoprecipitation
experiments (IP) and immunoﬂuorescence experiments (IF).
Table 5.5 Antibodies used for western blots (WB), immunoﬂuorescence (IF) and immunoprecipitation (IP) experiments
5.1.5 Buﬀers and media
Composition of the diﬀerent buﬀers andmedia used in this work will be speciﬁed under each individual
method.
5.1.6 Cell lines and bacteria
5.1.6.1 Cell lines
Cell line
HEK 293T
HeLa
Sf21
Description
Human embryonic kidney cell line expressing the SV40 large T-antigen
Cell line derived from a human cervix carcinoma
Cell line derived from the ovaries of Spodoptera frugiperda
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5.1.6.2 Bacteria
Strain
XL1-Blue
DH10BacTM
Genotype
endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F’[::Tn10 proAB+ lacIq
Δ(lacZ)M15] hsdR17(rK− mK+)
F−mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74
recA1 endA1 araD139 Δ(ara,leu)7697 galU galK λ− rpsL
nupG/bMON14272/pMON7124
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5.2 Methods
5.2.1 Cloning of DNA constructs
5.2.1.1 Polymerase chain reaction (PCR), restriction digestion and ligation
Standard PCR reactions were carried out using a 2-step Phusion Polymerase protocol from Thermo
Fisher Scientiﬁc. The composition of a standard reaction and the appropriate cycling conditions are
listed in Tab.5.6 and Tab.5.7 respectively. Either plasmid DNA or cDNA that was synthesized using the
First Strand cDNA Synthesis Kit (Thermo Fisher Scientiﬁc) was used as template for the ampliﬁcation
reaction.
Table 5.6 Composition of a standard 50 µl PCR reaction Table 5.7 Thermocycler program
X: 5 ng Plasmid DNA or 2 µl of a reverse transcription reaction that used 1 µg of total RNA
Ampliﬁed PCR products were separated on a 0.5% to 1% agorose gel (using 1 x TBE containing 0.01%
ethidium bromide (EtBr)) and the DNA products were isolated and puriﬁed using the NucleoSpin®Gel
and PCR Clean-up kit (MACHEREY-NAGEL GmbH). Compatible DNA overhangs were generated by incu-
bating both PCR product and target vector with the same FastDigest (Thermo Fisher Scientiﬁc) enzyme
pair. Reactionswere prepared as recommended by themanufacturer. In restriction reactions containing
plasmid DNA, 2U of FastAP thermosensitive Alkaline Phosphatase (Termo Fisher Scientitc) was added
to a 20 µl setup.
After incubation with the appropriate enzymes, PCR products were puriﬁed directly with the Nucle-
oSpin®kit. The linearized plasmid was ﬁrst subject to an agarose gel and after separation the plasmid
was retrieved from the gel and puriﬁed with the NucleoSpin®Gel and PCR Clean-up kit. Ligation re-
actions were carried out utilizing the puriﬁed vector and a 3-fold molar excess of the digested insert.
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Composition and reaction conditions followed the T4 DNA Ligase protocol of the manufacturer (Termo
Fisher Scientitc). After ligation, the complete reaction was utilized for the transfromation of E. coli cells.
1 x TBE 89mM Tris, 89mM boric acid, 2mM EDTA
5.2.1.2 Site-directed mutagenesis
Mutagenesis primers were designed according to QuikChange®Site-Directed Mutagenesis Kit manual
(Agilent Technologies). Reaction composition and cycler conditions used to amplify the modiﬁed plas-
mids are listed in Tab.5.8 and Tab.5.9 respectively.
Table 5.8 Composition of a site-directed
mutagenesis reaction
Table 5.9 Thermocycler program for a site-directed
mutagenesis reaction
DNA from the reaction was puriﬁed using the NucleoSpin®Gel and PCR Clean-up kit. Before the trans-
formation of E. coli cells, template DNA was removed from the reaction through enzymatic digestion.
For this, the FastDigest enzyme DpnI was applied to the reaction and incubated according to the man-
ufacturer’s protocol (Thermo Fisher Scientiﬁc).
5.2.1.3 Heat-shock trans formation of E. coli
Chemically competent E. coli cells of the strain XL1-Blue were used for transformations. Cells were
thawed on ice and then incubated for 10min with the plasmid DNA (obtained from the sections 5.2.1.1
and 5.2.1.2). Heat-shock was carried out at 42 ◦C for 1min in a thermoblock and the cells were af-
terwards directly transferred onto ice for another 10min. Cells transformed with plasmids harboring
an ampicillin resistance were plated directly onto LBAmp-plates and incubated at 37 ◦C1 until visible
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colonies were formed. For plasmids encoding other resistancemarkers (see Bac-to-Bacmanual referred
in section 5.2.3.3), cells were ﬁrst incubated for 1 h at 37 ◦C in LB medium that contain no antibiotics.
Afterwards, cells were concentrated via centrifugation (1min; 8000 xg) and resuspended in 70 µl of LB-
medium (no antibiotics). This suspension was then plated onto LB-plates containing the appropriate
antibiotic and cultivated at 37 ◦C.
LB
LB agar
LB/ LB agar with ampicillin
1% NaCl, 0.5% yeast extract, 1% tryptone, adjust pH to 7.2 - 7.5
LB medium, 1.5% agar
Ampicillin end concentration (100 µg/mL)
5.2.1.4 Isolation of plasmid DNA from E. coli
Plasmid DNA of diﬀerent quantities and of high purity were isolated using the NucleoBond®Plasmid
kit and NucleoBond®Xtra Midi kit from MACHEREY-NAGEL. The "Easyprep" method was used for the
screening of clones and was carried-out as published by Berghammer and Auer.220 Brieﬂy, 2ml of a
overnight culture was centrifuged at 17 000 xg for 1min to pellet the cells. Afterwards, the cells were
resuspended in 40 µL of Easyprep buﬀer, boiled for 1min at 99 ◦C and then transferred onto ice for
an additional minute. Cell debris was afterwards centrifuged down at 17 000 xg for 10min. 10 µL of
the supernatant was then used for a standard test digestion in order to screen for appropriate DNA
fragments during an agarose gel electrophoresis (see section 5.2.1.1).
Easyprep buﬀer 10mM Tris/HCl pH 8.0, 1mM EDTA, 15% saccharose, 2mg/mL lysozyme,
0.2mg/mL RNase A, 0.1mg/mL BSA
5.2.1.5 Sanger sequencing
DNA constructs were sequenced either by GATC Biotech AG (Konstanz, Germany) or Macrogen Europe
(Amsterdam, The Netherlands). Sequencing reactions were prepared as recommended by the compa-
nies. DNA oligonucleotides for sequencing were designed according to the speciﬁcations listed on the
GATC Biotech AG website (www.gatc-biotech.com).
68
5. Material and Methods
5.2.2 Cell culture
5.2.2.1 Cultivation of human cell lines
Human cell lines were cultivated under standard conditions (37 ◦C, 95% humidity and 5% CO2) in Dul-
becco’s modiﬁed Eagle medium (DMEM) supplemented with 10% FBS and 1% Penecillin-Streptomycin
mix (all from Sigma-Aldrich).
Cells were passaged once they have reached a conﬂuency of approximately 90%. Cells were rinsed
once with 1 x PBS and incubated for 5min at 37 ◦C with an amount of a 1 x trypsin-EDTA solution that
corresponded to 10% of the initial culture volume. The trypsin reaction is then stop through the addi-
tion of fully supplemented DMEM (FBS and antibiotics). A desired amount of cells was then transferred
into a new culture dish supplied with fresh medium.
1 x PBS 8 g/l NaCl, 0.2 g/l KCl, 1.78 g/l Na2HPO4 • (H2O), 0.24 g/l KH2PO4
Adjust pH to 7.5 and autoclave
5.2.2.2 Cultivation of Sf21 cells
The insect cell line Sf21 derived from Spodoptera frugiperdawas supplied with Sf-900™II SFM (Thermo
Fisher Scientiﬁc) and cultivated at 27 ◦C with constant agitation (55 to 70 rpm). Cell density of the
suspension culture was maintained between 1 to 4× 106 cells/ml. At higher densities, the cells were
subcultivated by diluting the cells down to 1× 106 cells/ml with Sf-900 medium.
5.2.3 Protein based methods
5.2.3.1 Expression of recombinant proteins in HEK 293T using Ca3(PO4)2
Large-scale recombinant protein production in HEK 293T cells was carried-out by transfecting the cells
using the Ca3(PO4)2-method. Prior to transfection, cells were seeded onto a 15 cm plate in order to
achieve a conﬂuency of approximately 25%. Transfection setups were then prepared as shown in
Tab.5.10 and directly added to the cells. Cells were afterwards further cultivated for 1 to 2 d under
standard conditions (see section 5.2.2.1).
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Table 5.10 Composition of a 2ml setup for the transfection of HEK 293T cells with Ca3(PO4)2
2 x HEPES-buﬀer 274mM NaCl, 1.5mM Na2HPO4 , 54.6mM HEPES pH 7.1
5.2.3.2 Expression of recombinant proteins in HeLa cells using Lipofectamine®2000
For the transfection of HeLa cells using Lipofectamine®2000 (Thermo Fisher Scientiﬁc), the cells were
cultivated in antibiotic-free DMEM andwere 90 to 95% conﬂuent prior to transfection. Lipid-DNA com-
plexeswere prepared inOpti-MEM®(Thermo Fisher Scientiﬁc) according to the protocol of themanufac-
turer. Cells were cultivated for 48 h after transfection before continuing any experiments. Transfections
were carried-out by Franziska Weichmann (University Regensburg, Biochemistry I).
5.2.3.3 Expression of recombinant proteins in Sf21 cells
Baculovirus stocks were essentially generated as described in the Bac-to-Bac manual (Thermo Fisher
Scientiﬁc). For the expression of recombinant proteins, 0.5 to 1 L cultures of Sf21 cells, with a cell con-
centration of 1× 106 cells/ml, were prepared. Cells were infected with 10ml of a P2 viral stock and
incubated at 27 ◦C for 72 hwhile constantly shaking. Cells were afterwards harvested via centrifugation
(700 xg, 10min, room temperature) and, after removal of the supernatant, utilized for lysate prepara-
tion (see section 5.2.3.6). If protein isolation should be conducted at a later time point, then the pelleted
cells are ﬂash-frozen in liquid nitrogen and stored by−80 ◦C.
5.2.3.4 Whole-cell lysate preparation from human cell lines
Cells transfected via the Ca3(PO4)2-method were washed twice with 1 x PBS and then detached from
the cultivation dishes using a cell scraper. The cell suspension was transferred into a 1.5ml reaction
tube and the cells were centrifuged for 10min at 500 xg and 4 ◦C. The resulting cell pellet was then
resuspended in CoIP lysis buﬀer (1ml per 15 cm plate) and incubated for 10min on ice. The resulting
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crude lysate was afterwards centrifuged at 17 000 xg for 10min and 4 ◦C to remove the cell debris. The
supernatant was then passed through a 0.45 um ﬁlter and transferred into a new reaction tube.
1 x CoIP lysis buﬀer 25mM Tris HCl pH 7.4, 150mM KCl , 0.5% NP-40 alternative, 2mM EDTA,
0.5mM AEBSF, 1mM DTT
5.2.3.5 Immunoprecipitation
For immunoprecipitation (IP) experiments, antibodies commercially purchased or provided by thework-
group of Elisabeth Kremmer were coupled to protein G sepharose beads (GE Healthcare). Both the
amount of beads and antibody were adjusted to the amount of lysate used for an experiment. Nor-
mally, 5 to 10 µg of puriﬁed antibody was added to 30 µl of beads. Prior to coupling, the beads were
washed three times with 1 x PBS (centrifugation: 1500 xg, 30 s, 4 ◦C). Antibody and beads were cou-
pled overnight at 4 ◦C, while the setup was constantly rotating. Antibodies that were not bound by the
beads were removed the next day by washing thrice with CoIP lysis buﬀer.
Input samples were taken before adding the coupled beads to the lysate. IP reactions were then incu-
bated at 4 ◦C and under constant rotation for 3 to 4 h. The beads were afterwards washed four times
with CoIP washing buﬀer. Proteins were eluted by adding 2 x Laemmli sample buﬀer to the beads and
boiling the IP setup for 5min at 95 ◦C. The beads are then centrifuged down (17 000 xg, 1min) and the
supernatant is loaded onto a sodium dodecyl sulfate polyacrylamide gel (SDS-PA, see section 5.2.3.10).
CoIP washing buﬀer 50mM Tris HCl pH 7.4, 300mM KCl , 0.1% NP-40 alternative, 1.5mM
MgCl2, 0.5mM AEBSF, 1mM DTT
5.2.3.6 Lysate preparation from Sf21 cells expressing GST-METTL3 and METTL14
Suspension cultures of Sf21 cells expressing GST-taggedMETTL3 and untaggedMETTL14 were harvested
by pelleting the cells at 700 xg for 10min at room temperature. Afterwards, the cell pellet was then
washed twice in 1 x PBS using the same centrifugation settings. The resulting pellet of the last washing
step is then resuspended in GST-lysis buﬀer. Cells were lysed via sonication (output setting: 4-5; duty
cycle: 50%) and the cell debris was removed by centrifugating at 40 000 xg for 1 h at 4 ◦C. The resulting
supernatant was then ﬁltered using a 0.45 µm diameter ﬁlter.
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GST lysis buﬀer 1.5M NaCl in 1 x PBS pH 7.0
5.2.3.7 HPLC purﬁcation of GST-METTL3/14
HPLC-puriﬁcation program was written and the Äkta puriﬁcation system (GE Healthcare) was operated
by Dr. Thomas Treiber (University Regensburg). Filtered lysate cotaining GST-taggedMETTL3was loaded
onto a 5ml GST-column and the bound proteins were washed with at least four column volumes of GST
lysis buﬀer. Elution of the column-bound proteins was achieved with 2 to 3 columnvolumes of GST elu-
tion buﬀer. The collected fractions were analyzed via SDS-PAGE (see 5.2.3.10) and fractions containing
the recombinant proteins were pooled together. Tobacco Etch Virus (TEV) protease was added to the
pooled sample that was then dialysed overnight in a cold room against 1 L of 1 x PBS (pH 7.0). The dia-
lyzed sample was afterwards concentrated using a Vivaspin centrifuge concentrator (Sartorius, cut-oﬀ
50 kDa). As a ﬁnal step, the concentrate was loaded onto a gel ﬁltration column packed with Superdex
200 resin (GE Healthcare). The column was equilibrated with gel ﬁltration buﬀer prior to loading of the
sample. Fractions containing the recombinant protein were then again pooled and concentrated (Vi-
vaspin). Glycerol was added to the concentrated protein (endconcentration: 8%) that was afterwards
ﬂash-frozen in liquid nitrogen and stored at−80 ◦C.
GST elution buﬀer
Gel ﬁltration buﬀer
50mM Tris, 20mM glutathione in 1 x PBS pH 7.0
80mM KCl, 1.5mMMgCl2, 15mM HEPES pH 7.9
5.2.3.8 GST-pulldown
Depending on the amount of lysate used in the experiment, 20 to 100 µl of Glutathione Sepharose™Fast
Flow beads (GE Healthcare) were washed three times with GST lysis buﬀer (centrifugation: 1500 xg,
4 ◦C). The equilibrated beads were then added to the ﬁltered lysate and incubated in a cold room for
3 h while constantly rotating. Afterwards, the lysate was removed and the beads were washed ﬁve
times with GST lysis buﬀer (centrifugation: 1500 xg, 1min, 4 ◦C). Proteins were eluted by adding 50 to
200 µl of elution buﬀer to the beads and incubating the setup for 30min at room temperature while
constantly shaking. This elution step was repeated once and the eluates were pooled.
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5.2.3.9 Methanol chloroform precipitation
Aqueous protein solutions were concentrated using the methanol chloroform precipitation method
according to Friedman et al.221 In brief, 400 µl of methanol and 100 µl of chloroform were added to
400 µl of a aqueous protein solution and mixed vigorously. The setup is then centrifuged at 17 000 xg
for 10min at room temperature to separate the phases. The upper methanol/H2O-phase is discarded
without disturbing the interphase. 400 µl of methanol is added ontop of the interphase and mixed vig-
orously again. Proteins are then pelleted at 17 000 xg for 10min and the resulting pellet is air-dried for
3min at room temperature. The pellet is then dissolved in 1 x Laemmli sample buﬀer.
5.2.3.10 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), Coomassie stain-
ing, western blotting and silver staining
For the electrophoretic separation of proteins, sodium dodecyl sulfate polyacrylamide (SDS-PA) gels
were prepared according to Laemmli.222 Protein samples supplementedwith sample buﬀerwere boiled
for 10min at 95 ◦C prior to loading. Gels were initially run at 170V and raised to 250V, after the
samples have passed the stacking gel. Separation was stopped when the bromophenol blue dye ran
out of the gel.
Separation gel
Stacking gel
1 x SDS running buﬀer
1 x Laemmli sample buﬀer
10 to 12% Acrylamide/Bis solution (37.5:1), 380mM Tris/HCl pH 8.8, 0.1%
SDS, 0.1% TEMED, 0.1% APS
5% Acrylamide/Bis solution (37.5:1), 125mM Tris/HCl pH 6.8, 0.1% SDS,
0.1% TEMED, 0.1% APS
25mM Tris/HCl pH 7.5, 192mM glycine, 1% SDS
60mM Tris/HCl pH 6.8, 2% SDS, 5% β-mercaptoethanol, 0.01% bro-
mophenol blue, 10% glycerol
Coomassie staining was performed by incubating the gel for 1 to 2 h at room temperature in staining
solution. Gels were afterwards rinsed thrice with Milli-Q-grade H2O and destained with the destaining
solution at room temperature, until visible bands were detected.
Coomassie staining solution
Destaining solution
10% acetic acid, 30% ethanol, 0.25% Coomassie R250
10% acetic acid, 30% ethanol
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For western blots, proteins were transferred (semi dry) onto a Hybond ECL membrane (GE Healthcare)
using Towbin blotting buﬀer and a constant current of 2A/cm2 for 80min. Membranes were blocked in
1 x TBST containing 5% skim milk for 1 h at 4 ◦C. Afterwards, the primary antibody, diluted in blocking
buﬀer, was added to the membrane and incubated overnight at 4 ◦C. Unbound antibody was removed
by washing the membrane three times with 1 x TBST. The membrane was then incubated with the sec-
ondary antibody, diluted in blocking buﬀer, for 1 h at 4 ◦C. The membrane is then washed again thrice
before documenting the results using the Odyssey scanner system (LI-COR Biosciences).
1 x Towbin blotting buﬀer
1 x TBS
1 x TBST
Blocking solution
192mM glycine, 25mM Tris/HCl pH 8.6, 20%methanol
150mM NaCl, 10mM Tris/HCl pH 8
150mM NaCl, 10mM Tris/HCl pH 8, 0.1% Tween 20
5% skim milk powder in 1 x TBST
Silver stainings were carried out using a modiﬁed protocol of the method published by Blum et al.223
First a gel was incubated in ﬁxation solution for 20min at room temperature. Afterwards, the gel was
washed sequentially with washing solutions 1, 2 and ddH2O for 10min at room temperature. The sensi-
tizer solution is then added to the gel for precisely 60 s. Next, three washing steps are carried-out using
ddH2O and afterwards the silver staining solution was added to the gel for 20min at room tempera-
ture. After this step, the gel was washed thrice with ddH2O and afterwards incubated with developer
until bands with the desired intensity appeared. The reaction was then stopped by incubating and later
storing the gel in stop solution.
Fixation solution
Washing solution 1
Washing solution 2
Sensitizer solution
Silver staining solution
Developer
Stop solution
50%methanol, 5% acetic acid
50% ethanol
30% ethanol
0.02% sodium thiosulfate
6mM silver nitrate, 0.0185% formaldehyde
2% sodium carbonate, 0.0185% formaldehyde,
0.0004% sodium thiosulfate
5% acetic acid
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5.2.3.11 In vitrom6A methylation assay
In vitro methylation reactions were prepared as shown in Tab.5.11. Reactions were incubated at 30 ◦C
for 1 h followed by an inactivation step (5min, 65 ◦C). After heat-inactivation, free 3H was removed
from the reaction using G25 spin columns (GE Healthcare) according to the manufacturer’s protocol.
10 µl of the ﬂow-through was then diluted in 1ml of Unisafe 1 scintillation cocktail (Zinsser analytic) and
the counts per minute (c.p.m.) were determined in a LS 6500 scintillation counter (Beckman).
Table 5.11 Composition of a 20 µlm6A in vitromethylation reaction
10 xm6A methylation buﬀer 0.8M KCl, 15mMMgCl2, 40% glycerol, 150mM HEPES pH 7.9
5.2.3.12 SAM-binding assay
A 20 µl reaction containing 1Ci of 3H-SAM (15Ci/mmol), 5 to 20 µg of the GST-taggedMETTL3/14 com-
plex and 1 x m6A reaction buﬀer was prepared and incubated for 10min at room temperature. The
setup was then UV irradiated (254 nm) for up to 30min. 30 µl of ddH2Owas then added to the reaction
that was afterwards subject to a gel ﬁltration clean-up using G25 spin columns. 1 x Laemmli sample
buﬀer was added to the setup that was afterwards separated on a 10% PA gel (see 5.2.3.10). The gel
was then incubated ﬁrst in ﬁxation solution and then in Amersham Amplify Fluorographic Reagent (GE
Healthcare), both for 30min at room temperature and under agitation. The gel was then dried for an
hour at 80 ◦C and then exposed to an BioMax X-ray ﬁlm (Kodak) for 1 to 2weekswhile stored at−80 ◦C.
Fixation solution 30% ethanol, 10% acetic acid
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5.2.3.13 Electrophoretic mobility shift assay (EMSA)
Various RNA substrates needed to be radiolabeled with γ-32-P before these were incubated together
with the recombinant protein complex. For the labeling of in vitro transcribed RNA, the nucleic acid
was ﬁrst dephosphorylated (see Tab. 5.12 for reaction composition) and subsequently phosphorylated
usingγ-32-P ATP (see Tab.5.13 for reaction composition). Dephosphorylation reactionswere incubated at
37 ◦C for 30min and the reactions were afterwards heat-inactivated for 20min at 75 ◦C. The complete
reaction was then used for the phosphorylation reaction that was carried-out at 37 ◦C for 1 h. 10 µl of
ddH2Owas added to the reaction and a G25-column (GE Healthcare) clean-upwas performed according
to the manufacturer’s protocol.
RNAs used in EMSAs that were chemically synthesized could be directly phosphorylated with radiola-
beled ATP using the T4-PNK protocol of the manufacturer (Thermo Fisher Scientiﬁc). After labeling, the
reactions followed the same clean-up step as those reactions utilizing in vitro transcribed RNA.
Table 5.12 Composition of a 10 µl dephosphorylation
reaction for EMSAs
Table 5.13 Composition of a 20 µl phosphorylation
reaction for EMSAs
Enzymes and buﬀer were purchased from Thermo Fisher Scientiﬁc
After labeling and the clean-up step, the radiolabeled substrate RNAwas diluted to obtain a 1 nMwork-
ing stock. Recombinant protein, RNA (5 fmol) and incubation buﬀer (1 x endconcentration) were mixed
together and the reactions were incubated for 30min on ice. 6% native PA gels were pre-run in 1 x
EMSA running buﬀer for 30min at 230V in a cold-room before loading the reactions. Samples were
separated for 3 h at 230V and the gel was afterwards disassembled and dried for 1 h at 80 ◦C. A blanked
storage phosphor screen was exposed to the dried gel overnight. The results were later documented
using the Personal Molecular Imager System (BioRad).
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10 x EMSA running buﬀer
5 x incubation buﬀer
6% native PA gel
450mM Tris/HCl pH 7, 450mM borate
50mMMOPS pH 7, 250mM KCl, 25mMMgCl2, 25% glycerol
6% acrylamide/ N,N’-methylene bis-acrylamide, (37.5 :1), 1 x EMSA running
buﬀer, 5% glycerol, 0.08% APS, 0.08% TEMED
5.2.3.14 Cross-linking-MS analysis of METTL3/14
Recombinant METTL3/14 was expressed in Sf21 cells and puriﬁed as described above (see sections
5.2.3.3 and 5.2.3.7). The protein concentration was adjusted to 1mg/L and sent to the group of Dr.
Franz Herzog (LMU, Munich). The following steps were then carried-out by Götz Hagemann (LMU, Mu-
nich).
Cross-linking of the 2-subunit METTL3/14complex was performed by mixing 50 µg of the complex with
650 µMof an equimolarmixture of isotopically light (d0) andheavy (d12) labeledBS3 (bis-sulfosuccinimi-
dylsuberate) for 30min at 37 ◦C. The reactionwas quenched by adding a ﬁnal concentration of 100mM
ammonium bicarbonate for 20min at 37 ◦C.
Cross-linked proteins were enzymatically digested by trypsin and cross-linked peptides were identi-
ﬁed by tandem mass-spectrometry.224,225 Cross-linked proteins were denatured by adding 2 sample
volumes of 8M urea and reduced by incubating with 5mM Tris(2-carboxyethyl)phosphin at 35 ◦C for
15min. Proteinswere alkylatedwith 10mM iodoacetamide for 35min at room temperature in the dark.
Samples were proteolytically digested using trypsin. For the trypic digest, proteins were ﬁrst incubated
with lysyl endopeptidase (1/50, w/w) for 2 h at 35 ◦C followed by the addition of trypsin (1/50, w/w) in
a setup that contained 1M urea. The reaction was carried-out overnight. Proteolysis was stopped by
the addition of 1%(v/v) triﬂuoroacetic acid (TFA).
Acidiﬁed peptides were puriﬁed by reversed-phase chromatography on C18 columns (Sep-Pak). Eluates
were dried, reconstituted in 20 µl of mobile phase (water/acetonitrile/TFA, 75:25:0.1) and cross-linked
peptides were enriched on a Superdex Peptide PC 3.2/30 column. Fractions of the cross-linked peptides
were analyzed by liquid chromatography coupled to tandem mass spectrometry using a LTQ Orbitrap
Elite (Thermo Scientiﬁc) instrument. The cross-link fragment ion spectra were searched and peptides
identiﬁed by the open-source software xQuest.225 The results were ﬁltered according to the following
parameters: score< 0.85, MS1 tolerance window of−4 ppm to 4 ppm and score≥ 22 andmanually val-
idated. The ﬁltered results were then visualized using the online tool xVis Crosslink Analysis Webserver
(https://xvis.genzentrum.lmu.de/CrossVisNoLogin.php).
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5.2.4 RNA based methods
5.2.4.1 Denaturing urea PAGE and blotting of RNA
Denaturing PA gels containing urea were casted as recommended by the manufacturer (National diag-
nostics or Roth). The percentage of the gel depended on the size of the RNA that should be analyzed.
The polymerized gel pre-ran for 30min at 400V before loading the samples. RNA samples were supple-
mented with 2 x RNA sample buﬀer and boiled for 3min at 95 ◦C and then loaded onto the gel. After
separation, the gel was disassembled and transferred into a staining solution (1 x TBE and 0.01% EtBr)
for 10min under steady agitation. To visualize the RNA, the gel was then placed on a UV light table and
the result were documented.
Blotting (semi dry) of radiolabeled RNA from in vitromethylation assays onto an Amersham Hybond-N
membrane (GE Healthcare) was carried-out at 20V for 30min using ddH2O as a buﬀer system. After
transfer of the RNA, the membrane was air-dried and exposed to a BioMax X-ray ﬁlm (Kodak) using a
TranScreen intensifying screen (GE Healthcare) for 1 to 2 weeks while stored at −80 ◦C (experiments
were conducted in cooperation with Dr. Thomas Treiber, University Regensburg).
2 x RNA sample buﬀer 0.05% xylene cyanol, 0.05% bromphenol blue in formaide
5.2.4.2 T7 in vitro transcription
Substrate RNA for in vitromethylation assays were synthesized using the T7 DNA-dependant RNA poly-
merase. The enzyme used for the transcription reaction was puriﬁed by Dr. Thomas Treiber and Dr.
Nora Treiber (both University Regensburg, Biochemistry I). A typical composition of a 1ml reaction is
shown in Tab.5.14.
Table 5.14 Composition of a 1ml T7 in vitro transcription reaction
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Reactions were incubated at 37 ◦C overnight and then stopped through the addition of 1ml of 2 x RNA
sample buﬀer. Samples were then electrophoretically separated on a urea PA gel (see 5.2.4.1) and the
RNA was visualized by UV shadowing. Transcripts of the correct size were cut-out of the gel and the
RNA was eluted overnight with H2O. The eluted transcript was then concentrated and desalted using a
Vivaspin concentrator (Sartorius) with an appropriate cut-oﬀ.
5.2.5 Immunﬂuorescence microscopy
Immunoﬂuorescence experiments were conducted by Franziska Weichmann (University Regensburg,
Biochemistry I) and followed the subsequent protocol. Transfected HeLa cells (see 5.2.3.2; also pre-
formed by Franziska Weichmann) were seeded into 24-well plates that contained a cover slip (12 mm
diameter; Roth) in each well. The cells were further cultivated for 24 h under standard conditions. Cells
were then washed twice with pre-warmed (37 ◦C) 1 x PBS-A and afterwards ﬁxated with ﬁxation buﬀer
(1ml, 10min, 37 ◦C). The cross-linking reaction was stopped by replacing the ﬁxation solution with
the same volume of PBS-G and incubating the cells for 10min at 37 ◦C. The sequential steps were
all carried-out at room temperature. Setups were washed twice with PBS-A and then 500 µl of per-
meabilization solution was added to the ﬁxated cells for 30min. Cells were rinsed once with blocking
buﬀer and then incubated for 30min in 500 µl of this buﬀer. The blocking buﬀer was then discarded
and replace by 500 µl of blocking buﬀer in which the primary antibody was diluted. After incubtaing the
cover slips for 1 h, the cells were washed four times with blocking solution and the secondary antibody
was then incubated for an additional hour. Setups were afterwards washed once with blocking buﬀer
and then three times with 1 x PBS-A. 10 µl of Prolong®Gold mounting medium supplemented with 4’,6-
diamidino-2-phenylindole (DAPI, Thermo Fisher Scientiﬁc) was then added on top of each cover slip that
were afterwards placed on a microscope slide. Setups were then dried for at least 12 h in the dark.
10 x PBS-A
Fixation buﬀer
PBS-G
Permeabilization buﬀer
Blocking buﬀer
2 g/L KCl, 2 g/L H2PO4, 80 g/L NaCl, 22 g/L Na2HPO4 • 7 H2O, adjust pH
to 7.4
4% paraformaldehyde in PBS-A
7.5 g/L glycine in PBS-A
0.2% Triton X-100 in PBS-A
0.05% Triton X-100, 50 g/L BSA (Cohn-Fraction V) in PBS-A
Slides were analyzed using a TCS SP8 (Leica Microsystems) confocal microscope. This instrument is
equipped with a 405 nm laser (for DAPI), an argon-ion laser (488 nm, for Alexa 488) and a DPSS laser
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(561 nm, for Alexa 555). All confocal images were recorded using a HC PL APO 63x/1,30 GLYC CORR CS2
objective.
5.2.6 Bioinformatic methods
5.2.6.1 Nucleotide and protein sequences of METTL3, METTL14 and WTAP used in this work
Nucleotide sequences used for the cloning of METTL3, METTL14 and WTAP expression vectors were
acquired from the NCBI database. For the diﬀerent proteins the following NCBI reference sequences
were used:
• METTL3 (NM_ 019852.3)
• METTL14 (NM_ 020961.2)
• WTAP (NM_ 004906.4)
The protein sequences of these genes were obtained by in silico translation of the abovementioned ref-
erence sequences using the program Serial Cloner (version 2.6; http://serialbasics.free.fr/Serial_Cloner.
html).
5.2.6.2 In silico secondary structure predication of proteins using Psipred
Secondary structures within the proteins METTL3, METTL14 and WTAP were predicted using the online
algorithm Psipred (http://bioinf.cs.ucl.ac.uk/psipred/).226 Strands are indicated by arrows, whereas α-
helices are represented by cylinders (see appendix). The retrieved predictions were used for the pre-
diction of the overall structure and the construction of truncations of the above mentioned proteins.
5.2.6.3 In silico predication of coiled-coil structures within proteins using COILS
For the prediction of coiled-coils within the proteins METTL3 andWTAP, the online tool COILS was used
(http://embnet.vital-it.ch/software/COILS_form.html).183 This algorithm scans the primary sequence
of the protein for heptad sequences that have been found to form coiled-coils.200 Sliding windows
of 14, 21 or 28 amino acids were applied in order to detect 2, 3 or 4 heptad sequences respectively.
Depending on the composition of the analyzed heptad sequence, each amino acid position is allocated
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a score between 0 and 1. The higher the score, the more likely the analyzed amino acid position fulﬁlls
the requirements to form a coiled-coil.
While using COILS, the following settings were used:
• Window width: all
• Matrix: MTIDK
• 2.5 fold weighting of positions a,d: yes
• Input sequence format: plain text
5.2.6.4 In silico prediction of nuclear localization signals using Eukaryotic LinearMotif resource tool
Nuclear localization sequences (NLS) were predicted using the Eukaryotic Linear Motif resource tool
(http://elm.eu.org/search/).180, 181 The default settings of this tool were used for the prediction of NLS
within METTL3, METTL14 and WTAP.
5.2.6.5 Quantiﬁcation of gel bands using ImageJ
Bands from gels were quantiﬁed using the tool ImageJ (https://imagej.nih.gov/ij/index.html). Quantiﬁ-
cation was carried out according to the protocol found on the website (https://imagej.nih.gov/ij/docs/
menus/analyze.html#gels, Chapter: Gels Submenu).
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The following ﬁgures contain the structure predictions of the proteinsMETTL3, METTL14 andWTAP that
were referred to in the sections 2.1 and 2.3. The ﬁgures were generated using the online tool Psipred
(see section 5.2.6.2). These structure predictions were used for the construction of Sf21 expression
constructs (designed and cloned by Dr. Nora Treiber, University Regensburg) and truncation variants of
METTL3 and WTAP (see sections 2.2 and 2.3 respectively).
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METTL3
Figure 6.1 Secondary structure prediction of METTL3 using the online tool Psipred
83
6.Appendix
METTL14
Figure 6.2 Secondary structure prediction of METTL14 using the online tool Psipred
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WTAP
Figure 6.3 Secondary structure prediction of WTAP using the online tool Psipred
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